<!DOCTYPE html PUBLIC "-">
<html>
<body class="spl" id="spl">
    <div class="DocumentTitle"><p class="DocumentTitle"><strong>LIPITOR- atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> trihydrate tablet, film coated </strong><br>Parke-Davis Div of Pfizer Inc<br></p></div>
    <div id="Highlights" class="Highlights">
        <table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed">
            <tr>
                <td align="left" valign="top">
                    <div>
                        <h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
                        <div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LIPITOR safely and effectively. See full prescribing information for LIPITOR.<br> <br>LIPITOR<span class="Sup">®</span> (atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>) Tablets for oral administration <br>Initial U.S. Approval: 1996</div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
                            <div>
                                <table class="Noautorules" width="80%">
                                    <col align="left" valign="top" width="75%">
                                    <col align="right" valign="top" width="25%">
                                    <tbody class="Headless">
                                        <tr>
                                            <td align="left">Dosage and Administration (<a href="#S2.6">2.6</a>)</td>
                                            <td align="right">10/2012</td>
                                        </tr>
                                        <tr>
                                            <td align="left">Warnings and Precautions (<a href="#S5.1">5.1</a>)</td>
                                            <td align="right">10/2012</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                        <div></div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
                            <div>
                                <p class="Highlighta">LIPITOR is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to:     </p>
                                <ul class="Disc">
                                    <li>Reduce the risk of MI, <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span>, revascularization procedures, and <span class="conditions" mdrptid="35205181" mdrpt="angina pectoris">angina</span> in patients without CHD, but with multiple risk factors (<a href="#S1.1">1.1</a>).</li>
                                    <li>Reduce the risk of MI and <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span> in patients with type 2 <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span> without CHD, but with multiple risk factors (<a href="#S1.1">1.1</a>).</li>
                                    <li>Reduce the risk of non-fatal MI, fatal and non-fatal <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span>, revascularization procedures, hospitalization for <span class="conditions" mdrptid="35205243" mdrpt="cardiac failure congestive">CHF</span>, and <span class="conditions" mdrptid="35205181" mdrpt="angina pectoris">angina</span> in patients with CHD (<a href="#S1.1">1.1</a>).</li>
                                    <li>Reduce elevated total-C, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, apo B, and TG levels and increase HDL-C in adult patients with primary <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">hyperlipidemia</span> (heterozygous familial and nonfamilial) and mixed <span class="conditions" mdrptid="36416641" mdrpt="dyslipidaemia">dyslipidemia</span> (<a href="#S1.2">1.2</a>).</li>
                                    <li>Reduce elevated TG in patients with <span class="conditions" mdrptid="36416637" mdrpt="hypertriglyceridaemia">hypertriglyceridemia</span> and primary dysbetalipoproteinemia (<a href="#S1.2">1.2</a>).</li>
                                    <li>Reduce total-C and <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C in patients with <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">homozygous familial hypercholesterolemia</span> (HoFH) (<a href="#S1.2">1.2</a>).</li>
                                    <li>Reduce elevated total-C, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">heterozygous familial hypercholesterolemia</span> after failing an adequate trial of diet therapy (<a href="#S1.2">1.2</a>).</li>
                                </ul>
                                <p class="Highlighta">Limitations of Use  </p>
                                <p class="Highlighta">LIPITOR has not been studied in <span class="Italics">Fredrickson </span>Types I and V dyslipidemias.  </p>
                            </div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
                            <div>
                                <p class="Highlighta">Dose range: 10 to 80 mg once daily (<a href="#S2.1">2.1</a>). </p>
                                <p class="Highlighta">Recommended start dose: 10 or 20 mg once daily (<a href="#S2.1">2.1</a>). </p>
                                <p class="Highlighta">Patients requiring large <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C reduction (&gt;45%) may start at 40 mg once daily (<a href="#S2.1">2.1</a>).  </p>
                                <p class="Highlighta">Pediatric starting dose: 10 mg once daily; maximum recommended dose: 20 mg once daily (<a href="#S2.2">2.2</a>). </p>
                            </div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
                            <div><p class="Highlighta">10, 20, 40, and 80 mg tablets (<a href="#S3">3</a>). </p></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
                            <div>
                                <p class="Highlighta">Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (<a href="#S4.1">4.1</a>). </p>
                                <p class="Highlighta">Women who are <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> or may become <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> (<a href="#S4.3">4.3</a>). </p>
                                <p class="Highlighta">Nursing mothers (<a href="#S4.4">4.4</a>). </p>
                                <p class="Highlighta"><span class="conditions" mdrptid="36009711" mdrpt="hypersensitivity">Hypersensitivity</span> to any component of this medication (<a href="#S4.2">4.2</a>). </p>
                            </div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
                            <div>
                                <p class="Highlighta">Skeletal muscle effects (e.g., <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> and <span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">rhabdomyolysis</span>): Risks increase when higher doses are used concomitantly with cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors). Predisposing factors include advanced age (&gt; 65), uncontrolled <span class="conditions" mdrptid="35506797" mdrpt="hypothyroidism">hypothyroidism</span>, and <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">renal impairment</span>. Rare cases of <span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">rhabdomyolysis</span> with <span class="conditions" mdrptid="37019319" mdrpt="renal failure acute">acute renal failure</span> secondary to <span class="conditions" mdrptid="35205334" mdrpt="myoglobinuria">myoglobinuria</span> have been reported. Advise patients to promptly report to their physician unexplained and/or persistent <span class="conditions" mdrptid="36516837" mdrpt="myalgia">muscle pain</span>, <span class="conditions" mdrptid="35809252" mdrpt="tenderness">tenderness</span>, or <span class="conditions" mdrptid="35809072" mdrpt="asthenia">weakness</span>. LIPITOR therapy should be discontinued if <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> is diagnosed or suspected (<a href="#S5.1">5.1</a>, <a href="#S8.5">8.5</a>). </p>
                                <br><p class="Highlighta">Liver enzyme abnormalities: Persistent elevations in hepatic <span class="conditions" mdrptid="36313602" mdrpt="transaminases">transaminases</span> can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter (<a href="#S5.2">5.2</a>). </p>
                                <br><p class="Highlighta">A higher incidence of <span class="conditions" mdrptid="36718010" mdrpt="haemorrhagic stroke">hemorrhagic stroke</span> was seen in patients without CHD but with <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span> or <span class="conditions" mdrptid="36718067" mdrpt="transient ischaemic attack">TIA</span> within the previous 6 months in the LIPITOR 80 mg group vs. placebo (<a href="#S5.5">5.5</a>).  </p>
                            </div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
                            <div>
                                <p class="Highlighta">The most commonly reported adverse reactions (incidence ≥ 2%) in patients treated with LIPITOR in placebo-controlled trials regardless of causality were: <span class="conditions" mdrptid="36110697" mdrpt="nasopharyngitis">nasopharyngitis</span>, <span class="conditions" mdrptid="36516812" mdrpt="arthralgia">arthralgia</span>, <span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">diarrhea</span>, <span class="conditions" mdrptid="36516959" mdrpt="pain in extremity">pain in extremity</span>, and <span class="conditions" mdrptid="36110736" mdrpt="urinary tract infection">urinary tract infection</span> (<a href="#S6.1">6.1</a>). </p>
                                <br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at (1-800-438-1985 and www.pfizer.com) or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
                            </div>
                            <div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                            </div>
                            <div></div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
                            <div>
                                <table width="90%">
                                    <caption><span>Drug Interactions Associated with Increased Risk of <span class="conditions" mdrptid="36516886" mdrpt="myopathy">Myopathy</span>/<span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">Rhabdomyolysis</span> (<a href="#S2.6">2.6</a>, <a href="#S5.1">5.1</a>, <a href="#S7">7</a>, <a href="#S12.3">12.3</a>)</span></caption>
                                    <col align="left" valign="top" width="50%">
                                    <col align="left" valign="top" width="50%">
                                    <tbody class="Headless">
                                        <tr class="Botrule First">
                                            <td class="Rrule" align="left">Interacting Agents </td>
                                            <td align="left">Prescribing Recommendations </td>
                                        </tr>
                                        <tr class="Botrule">
                                            <td class="Rrule" align="left">Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), <span class="conditions" mdrptid="35909578" mdrpt="hepatitis c">hepatitis C</span> protease inhibitor (telaprevir)</td>
                                            <td align="left" valign="middle">Avoid atorvastatin</td>
                                        </tr>
                                        <tr class="Botrule">
                                            <td class="Rrule" align="left">HIV protease inhibitor (lopinavir plus ritonavir)</td>
                                            <td align="left" valign="middle">Use with caution and lowest dose necessary</td>
                                        </tr>
                                        <tr class="Botrule">
                                            <td class="Rrule" align="left">Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir)</td>
                                            <td align="left" valign="middle">Do not exceed 20 mg atorvastatin daily</td>
                                        </tr>
                                        <tr class="Last">
                                            <td class="Rrule" align="left" valign="middle">HIV protease inhibitor (nelfinavir)<br><span class="conditions" mdrptid="35909578" mdrpt="hepatitis c">Hepatitis C</span> protease inhibitor (boceprevir)</td>
                                            <td align="left" valign="middle">Do not exceed 40 mg atorvastatin daily</td>
                                        </tr>
                                    </tbody>
                                </table>
                                <ul class="Disc">
                                    <li>Other Lipid-Lowering Medications: Use with fibrate products or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with LIPITOR (<a href="#S7">7</a>).</li>
                                    <li>Digoxin: Patients should be monitored appropriately (<a href="#S7.8">7.8</a>).</li>
                                    <li>Oral Contraceptives: Values for norethindrone and ethinyl estradiol may be increased (<a href="#S7.9">7.9</a>).</li>
                                    <li>Rifampin should be simultaneously co-administered with LIPITOR (<a href="#S7.7">7.7</a>).</li>
                                </ul>
                            </div>
                            <div>
                                <div></div>
                                <div></div>
                                <div></div>
                            </div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
                            <div><ul class="Disc"><li><span class="conditions" mdrptid="35909501" mdrpt="liver disorder">Hepatic impairment</span>: Plasma concentrations markedly increased in patients with chronic <span class="conditions" mdrptid="35909604" mdrpt="alcoholic liver disease">alcoholic liver disease</span> (<a href="#S12.3">12.3</a>).</li></ul></div>
                            <div><div></div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div></div>
                        <div></div>
                        <div>
                            <div></div>
                            <div></div>
                            <div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div>
                                    <div></div>
                                    <div></div>
                                    <div></div>
                                    <div></div>
                                    <div></div>
                                    <div></div>
                                </div>
                            </div>
                        </div>
                        <div><div></div></div>
                        <div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div></div>
                        <div><div></div></div>
                        <div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
                        <p class="HighlightsRevision">Revised: 5/2014</p>
                    </div>
                </td>
            </tr>
        </table>
    </div>
    <div id="Index" class="Index">
        <table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed">
            <tr>
                <td align="left" valign="top">
                    <div>
                        <h1 class="Colspan">
                            FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
                        </h1>
                        <h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
                        <h2><a href="#section-1.1" class="toc">1.1	<span class="conditions" mdrptid="37522077" mdrpt="prophylaxis">Prevention</span> of Cardiovascular Disease</a></h2>
                        <h2><a href="#section-1.2" class="toc">1.2	<span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">Hyperlipidemia</span></a></h2>
                        <h2><a href="#section-1.3" class="toc">1.3  Limitations of Use</a></h2>
                        <h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
                        <h2><a href="#section-2.1" class="toc">2.1  <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">Hyperlipidemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="conditions" mdrptid="36416641" mdrpt="dyslipidaemia">Dyslipidemia</span> <span class="Italics">(Fredrickson</span> Types IIa and IIb)</a></h2>
                        <h2><a href="#section-2.2" class="toc">2.2	<span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients (10–17 years of age)</a></h2>
                        <h2><a href="#section-2.3" class="toc">2.3  <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">Homozygous Familial Hypercholesterolemia</span></a></h2>
                        <h2><a href="#section-2.4" class="toc">2.4  Concomitant Lipid-Lowering Therapy</a></h2>
                        <h2><a href="#section-2.5" class="toc">2.5  Dosage in Patients With <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">Renal Impairment</span></a></h2>
                        <h2><a href="#section-2.6" class="toc">2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors</a></h2>
                        <h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
                        <h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
                        <h2><a href="#section-4.3" class="toc">4.3  <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span></a></h2>
                        <h2><a href="#section-4.4" class="toc">4.4  Nursing mothers</a></h2>
                        <h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
                        <h2><a href="#section-5.1" class="toc">5.1  Skeletal Muscle</a></h2>
                        <h2><a href="#section-5.2" class="toc">5.2  Liver Dysfunction</a></h2>
                        <h2><a href="#section-5.3" class="toc">5.3  Endocrine Function</a></h2>
                        <h2><a href="#section-5.4" class="toc">5.4  CNS Toxicity</a></h2>
                        <h2><a href="#section-5.5" class="toc">5.5  Use in Patients with Recent <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">Stroke</span> or <span class="conditions" mdrptid="36718067" mdrpt="transient ischaemic attack">TIA</span></a></h2>
                        <h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
                        <h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Adverse Experiences</a></h2>
                        <h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
                        <h2><a href="#section-6.3" class="toc">6.3	Pediatric Patients (ages 10–17 years)</a></h2>
                        <h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
                        <h2><a href="#section-7.1" class="toc">7.1  Strong Inhibitors of CYP 3A4</a></h2>
                        <h2><a href="#section-7.2" class="toc">7.2  Grapefruit Juice</a></h2>
                        <h2><a href="#section-7.3" class="toc">7.3  Cyclosporine</a></h2>
                        <h2><a href="#section-7.4" class="toc">7.4 Gemfibrozil</a></h2>
                        <h2><a href="#section-7.5" class="toc">7.5 Other Fibrates</a></h2>
                        <h2><a href="#section-7.6" class="toc">7.6 Niacin</a></h2>
                        <h2><a href="#section-7.7" class="toc">7.7  Rifampin or other Inducers of Cytochrome P450 3A4</a></h2>
                        <h2><a href="#section-7.8" class="toc">7.8  Digoxin</a></h2>
                        <h2><a href="#section-7.9" class="toc">7.9 Oral Contraceptives</a></h2>
                        <h2><a href="#section-7.10" class="toc">7.10  Warfarin</a></h2>
                        <h2><a href="#section-7.11" class="toc">7.11 Colchicine</a></h2>
                        <h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
                        <h2><a href="#section-8.1" class="toc">8.1  <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span></a></h2>
                        <h2><a href="#section-8.2" class="toc">8.3  Nursing Mothers</a></h2>
                        <h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
                        <h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
                        <h2><a href="#section-8.5" class="toc">8.6	<span class="conditions" mdrptid="35909501" mdrpt="liver disorder">Hepatic Impairment</span></a></h2>
                        <h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
                        <h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
                        <h1><a href="#section-11" class="toc">12   CLINICAL PHARMACOLOGY</a></h1>
                        <h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
                        <h2><a href="#section-11.2" class="toc">12.2	Pharmacodynamics</a></h2>
                        <h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
                        <h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
                        <h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
                        <h1><a href="#section-13" class="toc">14  CLINICAL STUDIES</a></h1>
                        <h2><a href="#section-13.1" class="toc">14.1  <span class="conditions" mdrptid="37522077" mdrpt="prophylaxis">Prevention</span> of Cardiovascular Disease</a></h2>
                        <h2><a href="#section-13.2" class="toc">14.2  <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">Hyperlipidemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="conditions" mdrptid="36416641" mdrpt="dyslipidaemia">Dyslipidemia</span> <span class="Italics">(Fredrickson</span> Types IIa and IIb)</a></h2>
                        <h2><a href="#section-13.3" class="toc">14.3  <span class="conditions" mdrptid="36416637" mdrpt="hypertriglyceridaemia">Hypertriglyceridemia</span> <span class="Italics">(Fredrickson</span> Type IV)</a></h2>
                        <h2><a href="#section-13.4" class="toc">14.4  Dysbetalipoproteinemia <span class="Italics">(Fredrickson</span> Type III)</a></h2>
                        <h2><a href="#section-13.5" class="toc">14.5  <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">Homozygous Familial Hypercholesterolemia</span></a></h2>
                        <h2><a href="#section-13.6" class="toc">14.6  <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients</a></h2>
                        <h1><a href="#section-14" class="toc">15  REFERENCES</a></h1>
                        <h1><a href="#section-15" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
                        <h1><a href="#section-16" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
                        <h2><a href="#section-16.1" class="toc">17.1	<span class="conditions" mdrptid="36516837" mdrpt="myalgia">Muscle Pain</span></a></h2>
                        <h2><a href="#section-16.2" class="toc">17.2 Liver Enzymes</a></h2>
                        <h2><a href="#section-16.3" class="toc">17.3	<span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span></a></h2>
                        <h2><a href="#section-16.4" class="toc">17.4 Breast-feeding</a></h2>
                        <dl class="Footnote">
                            <dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
                            <dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
                        </dl>
                    </div>
                </td>
            </tr>
        </table>
    </div>
    <div class="Contents">
        <span class="product-label-link" conceptid="36918942" conceptname="depression">Depression HOI test link</span>        
        <h1>FULL PRESCRIBING INFORMATION</h1>
        <div class="Section" data-sectionCode="48780-1">
            <a name="DLDE"></a><a name="section-1"></a><p></p>
        </div>
        <div class="Section" data-sectionCode="34067-9">
            <a name="S1"></a><a name="section-1"></a><p></p>
            <h1>1	INDICATIONS AND USAGE</h1>
            <p class="First">Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to <span class="conditions" mdrptid="36416634" mdrpt="hypercholesterolaemia">hypercholesterolemia</span>. <span class="conditions" mdrptid="37522151" mdrpt="drug therapy">Drug therapy</span> is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet. </p>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S1.1"></a><a name="section-1.1"></a><p></p>
                <h2>1.1	<span class="conditions" mdrptid="37522077" mdrpt="prophylaxis">Prevention</span> of Cardiovascular Disease</h2>
                <p class="First">In adult patients without clinically evident <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary heart disease</span>, but with multiple risk factors for <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary heart disease</span> such as age, smoking, <span class="conditions" mdrptid="37622529" mdrpt="hypertension">hypertension</span>, <span class="conditions" mdrptid="36313993" mdrpt="high density lipoprotein decreased">low HDL</span>-C, or a family history of early <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary heart disease</span>, LIPITOR is indicated to:</p>
                <ul class="Disc">
                    <li>Reduce the risk of <span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">myocardial infarction</span></li>
                    <li>Reduce the risk of <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span></li>
                    <li>Reduce the risk for revascularization procedures and <span class="conditions" mdrptid="35205181" mdrpt="angina pectoris">angina</span></li>
                </ul>
                <p>In patients with type 2 <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span>, and without clinically evident <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary heart disease</span>, but with multiple risk factors for <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary heart disease</span> such as <span class="conditions" mdrptid="35607430" mdrpt="retinopathy">retinopathy</span>, <span class="conditions" mdrptid="37019412" mdrpt="albuminuria">albuminuria</span>, smoking, or <span class="conditions" mdrptid="37622529" mdrpt="hypertension">hypertension</span>, LIPITOR is indicated to:</p>
                <ul class="Disc">
                    <li>Reduce the risk of <span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">myocardial infarction</span></li>
                    <li>Reduce the risk of <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span></li>
                </ul>
                <p>In patients with clinically evident <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary heart disease</span>, LIPITOR is indicated to:</p>
                <ul class="Disc">
                    <li>Reduce the risk of non-fatal <span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">myocardial infarction</span></li>
                    <li>Reduce the risk of fatal and non-fatal <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span></li>
                    <li>Reduce the risk for revascularization procedures</li>
                    <li>Reduce the risk of hospitalization for <span class="conditions" mdrptid="35205243" mdrpt="cardiac failure congestive">CHF</span></li>
                    <li>Reduce the risk of <span class="conditions" mdrptid="35205181" mdrpt="angina pectoris">angina</span></li>
                </ul>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S1.2"></a><a name="section-1.2"></a><p></p>
                <h2>1.2	<span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">Hyperlipidemia</span></h2>
                <p class="First">LIPITOR is indicated: </p>
                <ul class="Square">
                    <li>As an adjunct to diet to reduce elevated total-C, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, apo B, and TG levels and to increase HDL-C in patients with primary <span class="conditions" mdrptid="36416634" mdrpt="hypercholesterolaemia">hypercholesterolemia</span> (heterozygous familial and nonfamilial) and mixed <span class="conditions" mdrptid="36416641" mdrpt="dyslipidaemia">dyslipidemia</span> <span class="Italics">(Fredrickson </span>Types IIa and  IIb);</li>
                    <li>As an adjunct to diet for the treatment of patients with elevated serum TG levels <span class="Italics">(Fredrickson </span>Type IV);</li>
                    <li>For the treatment of patients with primary dysbetalipoproteinemia <span class="Italics">(Fredrickson </span>Type III) who do not respond adequately to  diet;</li>
                    <li>To reduce total-C and <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C in patients with <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">homozygous familial hypercholesterolemia</span> as an adjunct to other lipid-lowering treatments (e.g., <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> <span class="conditions" mdrptid="37521119" mdrpt="apheresis">apheresis</span>) or if such treatments are unavailable;</li>
                    <li>
                        As an adjunct to diet to reduce total-C, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">heterozygous familial hypercholesterolemia</span> if after an adequate trial of diet therapy the following findings are present: 							<ol class="LittleAlpha">
                            <li><span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C remains ≥ 190 mg/dL or</li>
                            <li>
                                <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C remains ≥ 160 mg/dL and: 									<ul class="Disc">
                                    <li>there is a positive family history of premature cardiovascular disease or</li>
                                    <li>two or more other CVD risk factors are present in the pediatric patient</li>
                                </ul>
                            </li>
                        </ol>
                    </li>
                </ul>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S1.3"></a><a name="section-1.3"></a><p></p>
                <h2>1.3  Limitations of Use</h2>
                <p class="First">LIPITOR has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons <span class="Italics">(Fredrickson </span>Types I and V).</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34068-7">
            <a name="S2"></a><a name="section-2"></a><p></p>
            <h1>2	DOSAGE AND ADMINISTRATION</h1>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S2.1"></a><a name="section-2.1"></a><p></p>
                <h2>2.1  <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">Hyperlipidemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="conditions" mdrptid="36416641" mdrpt="dyslipidaemia">Dyslipidemia</span> <span class="Italics">(Fredrickson</span> Types IIa and IIb)</h2>
                <p class="First">The recommended starting dose of LIPITOR is 10 or 20 mg once daily. Patients who require a large reduction in <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C (more than 45%) may be started at 40 mg once daily. The dosage range of LIPITOR is 10 to 80 mg once daily. LIPITOR can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of LIPITOR should be individualized according to patient characteristics such as goal of therapy and response (see current <span class="Italics">NCEP Guidelines</span>). After initiation and/or upon titration of LIPITOR, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S2.2"></a><a name="section-2.2"></a><p></p>
                <h2>2.2	<span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients (10–17 years of age)</h2>
                <p class="First">The recommended starting dose of LIPITOR is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy [see current<span class="Italics"> NCEP Pediatric Panel Guidelines</span>, <span class="Italics"><a href="#S12">Clinical Pharmacology (12)</a></span>, and<span class="Italics"><a href="#S1.2"> Indications and Usage (1.2)</a></span>]. Adjustments should be made at intervals of 4 weeks or more.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S2.3"></a><a name="section-2.3"></a><p></p>
                <h2>2.3  <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">Homozygous Familial Hypercholesterolemia</span></h2>
                <p class="First">The dosage of LIPITOR in patients with homozygous FH is 10 to 80 mg daily. LIPITOR should be used as an adjunct to other lipid-lowering treatments (e.g., <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> <span class="conditions" mdrptid="37521119" mdrpt="apheresis">apheresis</span>) in these patients or if such treatments are unavailable.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S2.4"></a><a name="section-2.4"></a><p></p>
                <h2>2.4  Concomitant Lipid-Lowering Therapy</h2>
                <p class="First">LIPITOR may be used with bile acid resins. The combination of HMG-CoA reductase inhibitors (statins) and fibrates should generally be used with caution [see <span class="Italics"><a href="#S5.1">Warnings and Precautions, Skeletal Muscle (5.1)</a>, <a href="#S7">Drug Interactions (7)</a></span>].</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S2.5"></a><a name="section-2.5"></a><p></p>
                <h2>2.5  Dosage in Patients With <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">Renal Impairment</span></h2>
                <p class="First"><span class="conditions" mdrptid="37019308" mdrpt="renal disorder">Renal disease</span> does not affect the plasma concentrations nor <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C reduction of LIPITOR; thus, dosage adjustment in patients with renal dysfunction is not necessary [see <span class="Italics"><a href="#S5.1">Warnings and Precautions, Skeletal Muscle (5.1)</a>, <a href="#S12.3">Clinical Pharmacology, Pharmacokinetics (12.3)</a></span>].</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S2.6"></a><a name="section-2.6"></a><p></p>
                <h2>2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors</h2>
                <p class="First" style="border-left:1px solid;">In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the <span class="conditions" mdrptid="35909578" mdrpt="hepatitis c">hepatitis C</span> protease inhibitor (telaprevir), therapy with LIPITOR should be avoided. In patients with HIV taking lopinavir plus ritonavir, caution should be used when prescribing LIPITOR and the lowest dose necessary employed. In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, therapy with LIPITOR should be limited to 20 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of LIPITOR is employed. <span class="XmChange">In patients taking the HIV protease inhibitor nelfinavir or the <span class="conditions" mdrptid="35909578" mdrpt="hepatitis c">hepatitis C</span> protease inhibitor boceprevir, therapy with LIPITOR should be limited to 40 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of LIPITOR is employed</span> [see <span class="Italics"><a href="#S5.1">Warnings and Precautions, Skeletal Muscle (5.1)</a>, <a href="#S7">Drug Interactions (7)</a></span>].</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="43678-2">
            <a name="S3"></a><a name="section-3"></a><p></p>
            <h1>3	DOSAGE FORMS AND STRENGTHS</h1>
            <p class="First">White, elliptical, film-coated tablets containing 10, 20, 40, and 80 mg atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>.</p>
        </div>
        <div class="Section" data-sectionCode="34070-3">
            <a name="S4"></a><a name="section-4"></a><p></p>
            <h1>4 CONTRAINDICATIONS</h1>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S4.1"></a><a name="section-4.1"></a><p></p>
                <h2>4.1  Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels</h2>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S4.2"></a><a name="section-4.2"></a><p></p>
                <h2>4.2  <span class="conditions" mdrptid="36009711" mdrpt="hypersensitivity">Hypersensitivity</span> to any component of this medication</h2>
            </div>
            <div class="Section" data-sectionCode="42228-7">
                <a name="S4.3"></a><a name="section-4.3"></a><p></p>
                <h2>4.3  <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span></h2>
                <p class="First">Women who are <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> or may become <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span><span class="Italics">.</span> LIPITOR may cause fetal harm when administered to a <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> woman. <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">Serum cholesterol</span> and <span class="conditions" mdrptid="36314070" mdrpt="blood triglycerides">triglycerides</span> increase during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">normal pregnancy</span>, and <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> or <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> derivatives are essential for fetal development. <span class="conditions" mdrptid="37622403" mdrpt="arteriosclerosis">Atherosclerosis</span> is a chronic process and discontinuation of lipid-lowering drugs during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> should have little impact on the outcome of long-term therapy of primary <span class="conditions" mdrptid="36416634" mdrpt="hypercholesterolaemia">hypercholesterolemia</span>. There are no adequate and well-controlled studies of LIPITOR use during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span>; however in rare reports, <span class="conditions" mdrptid="35305493" mdrpt="congenital anomaly">congenital</span> anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of <span class="conditions" mdrptid="35305516" mdrpt="teratogenicity">teratogenicity</span>. LIPITOR SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> while taking this drug, LIPITOR should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see<span class="Italics"><a href="#S8.1"> Use in Specific Populations (8.1)</a></span>].</p>
            </div>
            <div class="Section" data-sectionCode="34080-2">
                <a name="S4.4"></a><a name="section-4.4"></a><p></p>
                <h2>4.4  Nursing mothers</h2>
                <p class="First">It is not known whether atorvastatin is excreted into human milk; however a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require LIPITOR treatment should not breastfeed their infants [see <span class="Italics"><a href="#S8.3">Use in Specific Populations (8.3)</a></span>].</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="43685-7">
            <a name="S5"></a><a name="section-5"></a><p></p>
            <h1>5 WARNINGS AND PRECAUTIONS</h1>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S5.1"></a><a name="section-5.1"></a><p></p>
                <h2>5.1  Skeletal Muscle</h2>
                <p class="First"><span class="Bold">Rare cases of <span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">rhabdomyolysis</span> with <span class="conditions" mdrptid="37019319" mdrpt="renal failure acute">acute renal failure</span> secondary to <span class="conditions" mdrptid="35205334" mdrpt="myoglobinuria">myoglobinuria</span> have been reported with LIPITOR and with other drugs in this class.</span> A history of <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">renal impairment</span> may be a risk factor for the development of <span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">rhabdomyolysis</span>. Such patients merit closer monitoring for skeletal muscle effects. </p>
                <p>Atorvastatin, like other statins, occasionally causes <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span>, defined as muscle aches or <span class="conditions" mdrptid="36516876" mdrpt="muscular weakness">muscle weakness</span> in conjunction with increases in <span class="conditions" mdrptid="36312525" mdrpt="blood creatine phosphokinase">creatine phosphokinase</span> (<span class="conditions" mdrptid="36312525" mdrpt="blood creatine phosphokinase">CPK</span>) values &gt;10 times ULN. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span>/<span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">rhabdomyolysis</span>.</p>
                <p style="border-left:1px solid;"><span class="XmChange">There have been rare reports of immune-mediated necrotizing <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> (IMNM), an autoimmune <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span>, associated with statin use.  IMNM is characterized by: proximal <span class="conditions" mdrptid="36516876" mdrpt="muscular weakness">muscle weakness</span> and elevated serum <span class="conditions" mdrptid="36312525" mdrpt="blood creatine phosphokinase">creatine kinase</span>, which persist despite discontinuation of statin treatment; muscle <span class="conditions" mdrptid="36313870" mdrpt="biopsy">biopsy</span> showing necrotizing <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> without significant <span class="conditions" mdrptid="35809181" mdrpt="inflammation">inflammation</span>; improvement with immunosuppressive agents.</span></p>
                <p style="border-left:1px solid;"><span class="XmChange"><span class="conditions" mdrptid="36516886" mdrpt="myopathy">Myopathy</span> should be considered in any patient with diffuse myalgias, muscle <span class="conditions" mdrptid="35809252" mdrpt="tenderness">tenderness</span> or <span class="conditions" mdrptid="35809072" mdrpt="asthenia">weakness</span>, and/or marked elevation of <span class="conditions" mdrptid="36312525" mdrpt="blood creatine phosphokinase">CPK</span>. Patients should be advised to report promptly unexplained <span class="conditions" mdrptid="36516837" mdrpt="myalgia">muscle pain</span>, <span class="conditions" mdrptid="35809252" mdrpt="tenderness">tenderness</span>, or <span class="conditions" mdrptid="35809072" mdrpt="asthenia">weakness</span>, particularly if accompanied by <span class="conditions" mdrptid="35809079" mdrpt="malaise">malaise</span> or <span class="conditions" mdrptid="35809054" mdrpt="pyrexia">fever</span> or if muscle signs and symptoms persist after discontinuing LIPITOR. LIPITOR therapy should be discontinued if markedly elevated <span class="conditions" mdrptid="36312525" mdrpt="blood creatine phosphokinase">CPK</span> levels occur or <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> is diagnosed or suspected.</span></p>
                <p>The risk of <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the <span class="conditions" mdrptid="35909578" mdrpt="hepatitis c">hepatitis C</span> protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with LIPITOR and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of <span class="conditions" mdrptid="36516837" mdrpt="myalgia">muscle pain</span>, <span class="conditions" mdrptid="35809252" mdrpt="tenderness">tenderness</span>, or <span class="conditions" mdrptid="35809072" mdrpt="asthenia">weakness</span>, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs (see <span class="Italics"><a href="#S7">Drug Interactions (7)</a></span>). Periodic <span class="conditions" mdrptid="36312525" mdrpt="blood creatine phosphokinase">creatine phosphokinase</span> (<span class="conditions" mdrptid="36312525" mdrpt="blood creatine phosphokinase">CPK</span>) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span>.</p>
                <p>Prescribing recommendations for interacting agents are summarized in Table 1 [see also <span class="Italics"><a href="#S2.6">Dosage and Administration (2.6)</a>, <a href="#S7">Drug Interactions (7)</a></span>, <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].      </p>
                <a name="table1"></a><table width="75%">
                    <caption><span>Table 1. Drug Interactions Associated with Increased Risk of <span class="conditions" mdrptid="36516886" mdrpt="myopathy">Myopathy</span>/<span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">Rhabdomyolysis</span></span></caption>
                    <col align="left" valign="top" width="50%">
                    <col align="left" valign="top" width="50%">
                    <thead>
                        <tr class="First Last">
                            <th align="left">Interacting Agents</th>
                            <th class="Lrule" align="left">Prescribing Recommendations </th>
                        </tr>
                    </thead>
                    <tfoot>
                        <tr>
                            <td colspan="2" align="left">
                                <dl class="Footnote">
                                    <dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
                                    <dd>Use with caution and with the lowest dose necessary (<a href="#S12.3">12.3</a>)</dd>
                                </dl>
                            </td>
                        </tr>
                    </tfoot>
                    <tbody>
                        <tr class="Botrule First">
                            <td class="Rrule" align="left">
                                Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), <span class="conditions" mdrptid="35909578" mdrpt="hepatitis c">hepatitis C</span> protease inhibitor (telaprevir)<br>
                            </td>
                            <td align="left" valign="middle">Avoid atorvastatin</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Rrule" align="left">
                                HIV protease inhibitor (lopinavir plus ritonavir)<br>
                            </td>
                            <td align="left" valign="middle">Use with caution and lowest dose necessary</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Rrule" align="left">Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir)</td>
                            <td align="left" valign="middle">Do not exceed 20 mg atorvastatin daily</td>
                        </tr>
                        <tr class="Last">
                            <td class="Rrule" align="left" valign="middle">HIV protease inhibitor (nelfinavir) <br><span class="conditions" mdrptid="35909578" mdrpt="hepatitis c">Hepatitis C</span> protease inhibitor (boceprevir)</td>
                            <td align="left" valign="middle">Do not exceed 40 mg atorvastatin daily</td>
                        </tr>
                    </tbody>
                </table>
                <p>Cases of <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span>, including <span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">rhabdomyolysis</span>, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see <span class="Italics"><a href="#S7.11">Drug Interactions (7.11)</a></span>].</p>
                <p><span class="Bold">LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> or having a risk factor predisposing to the development of <span class="conditions" mdrptid="37019318" mdrpt="renal failure">renal failure</span> secondary to <span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">rhabdomyolysis</span> (e.g., severe acute <span class="conditions" mdrptid="36110552" mdrpt="infection">infection</span>, <span class="conditions" mdrptid="37622449" mdrpt="hypotension">hypotension</span>, major <span class="conditions" mdrptid="37522270" mdrpt="surgery">surgery</span>, <span class="conditions" mdrptid="36211303" mdrpt="injury">trauma</span>, severe metabolic, endocrine and electrolyte disorders, and uncontrolled <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizures</span>).</span></p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S5.2"></a><a name="section-5.2"></a><p></p>
                <h2>5.2  Liver Dysfunction</h2>
                <p class="First">Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. <span class="Bold">Persistent elevations (&gt;3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum <span class="conditions" mdrptid="36313602" mdrpt="transaminases">transaminases</span> occurred in 0.7% of patients who received LIPITOR in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.</span></p>
                <p>One patient in clinical trials developed <span class="conditions" mdrptid="35104306" mdrpt="jaundice">jaundice</span>. Increases in <span class="conditions" mdrptid="36313593" mdrpt="liver function test">liver function tests</span> (LFT) in other patients were not associated with <span class="conditions" mdrptid="35104306" mdrpt="jaundice">jaundice</span> or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of LIPITOR.</p>
                <p>It is recommended that liver enzyme tests be obtained prior to initiating therapy with LIPITOR and repeated as clinically indicated. There have been rare postmarketing reports of fatal and non-fatal <span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">hepatic failure</span> in patients taking statins, including atorvastatin. If serious <span class="conditions" mdrptid="35909503" mdrpt="liver injury">liver injury</span> with clinical symptoms and/or <span class="conditions" mdrptid="35104304" mdrpt="hyperbilirubinaemia">hyperbilirubinemia</span> or <span class="conditions" mdrptid="35104306" mdrpt="jaundice">jaundice</span> occurs during treatment with LIPITOR, promptly interrupt therapy. If an alternate etiology is not found, do not restart LIPITOR.</p>
                <p>LIPITOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of LIPITOR [see <span class="Italics"><a href="#S4.1">Contraindications (4.1)</a></span>].</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S5.3"></a><a name="section-5.3"></a><p></p>
                <h2>5.3  Endocrine Function</h2>
                <p class="First">Increases in <span class="conditions" mdrptid="36314181" mdrpt="glycosylated haemoglobin">HbA1c</span> and <span class="conditions" mdrptid="37420500" mdrpt="fasting">fasting</span> <span class="conditions" mdrptid="36314155" mdrpt="blood glucose">serum glucose</span> levels have been reported with HMG-CoA reductase inhibitors, including LIPITOR.</p>
                <p>Statins interfere with <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that LIPITOR does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Caution should be exercised if a statin is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S5.4"></a><a name="section-5.4"></a><p></p>
                <h2>5.4  CNS Toxicity</h2>
                <p class="First">Brain <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">hemorrhage</span> was seen in a female dog treated for 3 months at 120 mg/kg/day. Brain <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">hemorrhage</span> and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0–24 hours) based on the maximum human dose of 80 mg/day. A single <span class="conditions" mdrptid="36718542" mdrpt="tonic convulsion">tonic convulsion</span> was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0–24) based on the maximum recommended human dose of 80 mg/day.</p>
                <p>CNS vascular lesions, characterized by perivascular hemorrhages, <span class="conditions" mdrptid="35809225" mdrpt="oedema">edema</span>, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class. A chemically similar drug in this class produced optic <span class="conditions" mdrptid="36718337" mdrpt="nerve degeneration">nerve degeneration</span> (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean <span class="conditions" mdrptid="36316180" mdrpt="drug level">drug level</span> in humans taking the highest recommended dose.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S5.5"></a><a name="section-5.5"></a><p></p>
                <h2>5.5  Use in Patients with Recent <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">Stroke</span> or <span class="conditions" mdrptid="36718067" mdrpt="transient ischaemic attack">TIA</span></h2>
                <p class="First">In a post-hoc analysis of the <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">Stroke</span> <span class="conditions" mdrptid="37522077" mdrpt="prophylaxis">Prevention</span> by Aggressive Reduction in <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">Cholesterol</span> Levels (SPARCL) study where LIPITOR 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span> or <span class="conditions" mdrptid="36718067" mdrpt="transient ischaemic attack">TIA</span> within the preceding 6 months, a higher incidence of <span class="conditions" mdrptid="36718010" mdrpt="haemorrhagic stroke">hemorrhagic stroke</span> was seen in the LIPITOR 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal <span class="conditions" mdrptid="36718010" mdrpt="haemorrhagic stroke">hemorrhagic stroke</span> was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively). The incidence of nonfatal <span class="conditions" mdrptid="36718010" mdrpt="haemorrhagic stroke">hemorrhagic stroke</span> was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span> on study entry, were associated with a higher incidence of <span class="conditions" mdrptid="36718010" mdrpt="haemorrhagic stroke">hemorrhagic stroke</span> in the atorvastatin group [see <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>]. </p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34084-4">
            <a name="S6"></a><a name="section-6"></a><p></p>
            <h1>6 ADVERSE REACTIONS</h1>
            <p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label:</p>
            <p><span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">Rhabdomyolysis</span> and <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>]</p>
            <p>Liver enzyme abnormalities [see <span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a></span>]</p>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S6.1"></a><a name="section-6.1"></a><p></p>
                <h2>6.1 Clinical Trial Adverse Experiences</h2>
                <p class="First">Because clinical trials are conducted under widely varying conditions, the <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">adverse reaction</span> rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
                <p>In the LIPITOR placebo-controlled clinical trial database of 16,066 patients (8755 LIPITOR vs. 7311 placebo; age range 10–93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on LIPITOR and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality. The five most common adverse reactions in patients treated with LIPITOR that led to treatment discontinuation and occurred at a rate greater than placebo were: <span class="conditions" mdrptid="36516837" mdrpt="myalgia">myalgia</span> (0.7%), <span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">diarrhea</span> (0.5%), <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span> (0.4%), <span class="conditions" mdrptid="36313524" mdrpt="alanine aminotransferase increased">alanine aminotransferase increase</span> (0.4%), and <span class="conditions" mdrptid="36313582" mdrpt="hepatic enzyme">hepatic enzyme</span> increase (0.4%). </p>
                <p>The most commonly reported adverse reactions (incidence ≥ 2% and greater than placebo) regardless of causality, in patients treated with LIPITOR in placebo controlled trials (n=8755) were: <span class="conditions" mdrptid="36110697" mdrpt="nasopharyngitis">nasopharyngitis</span> (8.3%), <span class="conditions" mdrptid="36516812" mdrpt="arthralgia">arthralgia</span> (6.9%), <span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">diarrhea</span> (6.8%), <span class="conditions" mdrptid="36516959" mdrpt="pain in extremity">pain in extremity</span> (6.0%), and <span class="conditions" mdrptid="36110736" mdrpt="urinary tract infection">urinary tract infection</span> (5.7%). </p>
                <p>Table 2 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in ≥ 2% and at a rate greater than placebo in patients treated with LIPITOR (n=8755), from seventeen placebo-controlled trials. </p>
                <a name="table2"></a><table width="100%">
                    <caption><span>Table 2. Clinical adverse reactions occurring in ≥ 2% in patents treated with any dose of LIPITOR and at an incidence greater than placebo regardless of causality (% of patients).</span></caption>
                    <col align="left" valign="middle" width="22%">
                    <col align="left" valign="middle" width="13%">
                    <col align="left" valign="middle" width="13%">
                    <col align="left" valign="middle" width="13%">
                    <col align="left" valign="middle" width="13%">
                    <col align="left" valign="middle" width="13%">
                    <col align="left" valign="middle" width="13%">
                    <thead>
                        <tr class="First Last">
                            <th class="Lrule" align="left">
                                <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">Adverse Reaction</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
                            </th>
                            <th align="left">Any dose<br>N=8755 </th>
                            <th align="left">10 mg<br>N=3908</th>
                            <th align="left">20 mg<br>N=188 </th>
                            <th align="left">40 mg<br>N=604 </th>
                            <th align="left">80 mg<br>N=4055</th>
                            <th class="Rrule" align="left">Placebo<br>N=7311</th>
                        </tr>
                    </thead>
                    <tfoot>
                        <tr>
                            <td colspan="7" align="left">
                                <dl class="Footnote">
                                    <dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
                                    <dd><span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">Adverse Reaction</span> ≥ 2% in any dose greater than placebo</dd>
                                </dl>
                            </td>
                        </tr>
                    </tfoot>
                    <tbody>
                        <tr class="First">
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="36110697" mdrpt="nasopharyngitis">Nasopharyngitis</span></td>
                            <td align="left">8.3</td>
                            <td align="left">12.9</td>
                            <td align="left">5.3</td>
                            <td align="left">7.0</td>
                            <td align="left">4.2</td>
                            <td class="Rrule" align="left">8.2</td>
                        </tr>
                        <tr>
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="36516812" mdrpt="arthralgia">Arthralgia</span></td>
                            <td align="left">6.9</td>
                            <td align="left">8.9</td>
                            <td align="left">11.7</td>
                            <td align="left">10.6</td>
                            <td align="left">4.3</td>
                            <td class="Rrule" align="left">6.5</td>
                        </tr>
                        <tr>
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">Diarrhea</span></td>
                            <td align="left">6.8</td>
                            <td align="left">7.3</td>
                            <td align="left">6.4</td>
                            <td align="left">14.1</td>
                            <td align="left">5.2</td>
                            <td class="Rrule" align="left">6.3</td>
                        </tr>
                        <tr>
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="36516959" mdrpt="pain in extremity">Pain in extremity</span></td>
                            <td align="left">6.0</td>
                            <td align="left">8.5</td>
                            <td align="left">3.7</td>
                            <td align="left">9.3</td>
                            <td align="left">3.1</td>
                            <td class="Rrule" align="left">5.9</td>
                        </tr>
                        <tr>
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="36110736" mdrpt="urinary tract infection">Urinary tract infection</span> </td>
                            <td align="left">5.7</td>
                            <td align="left">6.9</td>
                            <td align="left">6.4</td>
                            <td align="left">8.0</td>
                            <td align="left">4.1</td>
                            <td class="Rrule" align="left">5.6</td>
                        </tr>
                        <tr>
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="35708139" mdrpt="dyspepsia">Dyspepsia</span></td>
                            <td align="left">4.7</td>
                            <td align="left">5.9</td>
                            <td align="left">3.2</td>
                            <td align="left">6.0</td>
                            <td align="left">3.3</td>
                            <td class="Rrule" align="left">4.3</td>
                        </tr>
                        <tr>
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="35708202" mdrpt="nausea">Nausea</span></td>
                            <td align="left">4.0</td>
                            <td align="left">3.7</td>
                            <td align="left">3.7</td>
                            <td align="left">7.1</td>
                            <td align="left">3.8</td>
                            <td class="Rrule" align="left">3.5</td>
                        </tr>
                        <tr>
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">Musculoskeletal pain</span></td>
                            <td align="left">3.8</td>
                            <td align="left">5.2</td>
                            <td align="left">3.2</td>
                            <td align="left">5.1</td>
                            <td align="left">2.3</td>
                            <td class="Rrule" align="left">3.6</td>
                        </tr>
                        <tr>
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="36516848" mdrpt="muscle spasms">Muscle Spasms</span></td>
                            <td align="left">3.6</td>
                            <td align="left">4.6</td>
                            <td align="left">4.8</td>
                            <td align="left">5.1</td>
                            <td align="left">2.4</td>
                            <td class="Rrule" align="left">3.0</td>
                        </tr>
                        <tr>
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="36516837" mdrpt="myalgia">Myalgia</span></td>
                            <td align="left">3.5</td>
                            <td align="left">3.6</td>
                            <td align="left">5.9</td>
                            <td align="left">8.4</td>
                            <td align="left">2.7</td>
                            <td class="Rrule" align="left">3.1</td>
                        </tr>
                        <tr>
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="36718555" mdrpt="insomnia">Insomnia</span></td>
                            <td align="left">3.0</td>
                            <td align="left">2.8</td>
                            <td align="left">1.1</td>
                            <td align="left">5.3</td>
                            <td align="left">2.8</td>
                            <td class="Rrule" align="left">2.9</td>
                        </tr>
                        <tr class="Last">
                            <td class="Lrule" align="left"><span class="conditions" mdrptid="35708628" mdrpt="oropharyngeal pain">Pharyngolaryngeal pain</span></td>
                            <td align="left">2.3</td>
                            <td align="left">3.9</td>
                            <td align="left">1.6</td>
                            <td align="left">2.8</td>
                            <td align="left">0.7</td>
                            <td class="Rrule" align="left">2.1</td>
                        </tr>
                    </tbody>
                </table>
                <p>Other adverse reactions reported in placebo-controlled studies include:</p>
                <p><span class="Italics">Body as a whole</span>: <span class="conditions" mdrptid="35809079" mdrpt="malaise">malaise</span>, <span class="conditions" mdrptid="35809054" mdrpt="pyrexia">pyrexia</span>; <span class="Italics">Digestive system: </span><span class="conditions" mdrptid="35708164" mdrpt="abdominal discomfort">abdominal discomfort</span>, <span class="conditions" mdrptid="35708141" mdrpt="eructation">eructation</span>, <span class="conditions" mdrptid="35708153" mdrpt="flatulence">flatulence</span>, <span class="conditions" mdrptid="35909613" mdrpt="hepatitis">hepatitis</span>, <span class="conditions" mdrptid="35909469" mdrpt="cholestasis">cholestasis</span>; <span class="Italics">Musculoskeletal system</span>: <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">musculoskeletal pain</span>, <span class="conditions" mdrptid="36516843" mdrpt="muscle fatigue">muscle fatigue</span>, <span class="conditions" mdrptid="36516958" mdrpt="neck pain">neck pain</span>, <span class="conditions" mdrptid="36516818" mdrpt="joint swelling">joint swelling</span>; <span class="Italics">Metabolic and nutritional system</span>: <span class="conditions" mdrptid="36313602" mdrpt="transaminases">transaminases</span> increase, <span class="conditions" mdrptid="36313594" mdrpt="liver function test abnormal">liver function test abnormal</span>, <span class="conditions" mdrptid="36312565" mdrpt="blood alkaline phosphatase">blood alkaline phosphatase</span> increase, <span class="conditions" mdrptid="36312525" mdrpt="blood creatine phosphokinase">creatine phosphokinase</span> increase, <span class="conditions" mdrptid="35506628" mdrpt="hyperglycaemia">hyperglycemia</span>; <span class="Italics"><span class="conditions" mdrptid="36918860" mdrpt="nervousness">Nervous</span> system</span>: <span class="conditions" mdrptid="36919207" mdrpt="nightmare">nightmare</span>; <span class="Italics">Respiratory system: </span><span class="conditions" mdrptid="37220014" mdrpt="epistaxis">epistaxis</span>; <span class="Italics">Skin and appendages</span>: <span class="conditions" mdrptid="36009783" mdrpt="urticaria">urticaria</span>; <span class="Italics">Special senses</span>: <span class="conditions" mdrptid="35607483" mdrpt="vision blurred">vision blurred</span>, <span class="conditions" mdrptid="35406391" mdrpt="tinnitus">tinnitus</span>; <span class="Italics">Urogenital system:</span> <span class="conditions" mdrptid="36315740" mdrpt="white blood cells urine positive">white blood cells urine positive</span>. </p>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-6.1.1"></a><p></p>
                    <p class="First"><span class="Italics">Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)</span></p>
                    <p>In ASCOT [see<span class="Italics"><a href="#S14.1"> Clinical Studies (14.1)</a></span>] involving 10,305 participants (age range 40–80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with LIPITOR 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with LIPITOR was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up. </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-6.1.2"></a><p></p>
                    <p class="First"><span class="Italics">Collaborative Atorvastatin <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">Diabetes</span> Study (CARDS)</span></p>
                    <p>In CARDS [see <span class="Italics"><a href="#S14.1">Clinical Studies (14.1)</a></span>] involving 2,838 subjects (age range 39–77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with type 2 <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span> treated with LIPITOR 10 mg daily (n=1,428) or placebo (n=1,410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years. No cases of <span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">rhabdomyolysis</span> were reported.</p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-6.1.3"></a><p></p>
                    <p class="First"><span class="Italics">Treating to New Targets Study (TNT)</span></p>
                    <p>In TNT [see <span class="Italics"><a href="#S14.1">Clinical Studies (14.1)</a></span>] involving 10,001 subjects (age range 29–78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with LIPITOR 10 mg daily (n=5006) or LIPITOR 80 mg daily (n=4995), there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, respectively) during a median follow-up of 4.9 years. Persistent transaminase elevations (≥3 × ULN twice within 4–10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. Elevations of CK (≥ 10 × ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%).</p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-6.1.4"></a><p></p>
                    <p class="First"><span class="Italics">Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL)</span></p>
                    <p>In IDEAL [see <span class="Italics"><a href="#S14.1">Clinical Studies (14.1)</a></span>] involving 8,888 subjects (age range 26–80 years, 19% women; 99.3% Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with LIPITOR 80 mg/day (n=4439) or simvastatin 20–40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years.</p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-6.1.5"></a><p></p>
                    <p class="First"><span class="Italics"><span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">Stroke</span> <span class="conditions" mdrptid="37522077" mdrpt="prophylaxis">Prevention</span> by Aggressive Reduction in <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">Cholesterol</span> Levels (SPARCL)</span></p>
                    <p>In SPARCL involving 4731 subjects (age range 21–92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident CHD but with a <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span> or transient ischemic attack (<span class="conditions" mdrptid="36718067" mdrpt="transient ischaemic attack">TIA</span>) within the previous 6 months treated with LIPITOR 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations (≥ 3 × ULN twice within 4–10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK (&gt;10 × ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">Diabetes</span> was reported as an <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">adverse reaction</span> in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group [see <span class="Italics"><a href="#S5.5">Warnings and Precautions (5.5)</a></span>].</p>
                    <p>In a post-hoc analysis, LIPITOR 80 <span class="conditions" mdrptid="36316371" mdrpt="blood magnesium decreased">mg reduced</span> the incidence of <span class="conditions" mdrptid="36718016" mdrpt="ischaemic stroke">ischemic stroke</span> (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of <span class="conditions" mdrptid="36718010" mdrpt="haemorrhagic stroke">hemorrhagic stroke</span> (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo. The incidence of fatal <span class="conditions" mdrptid="36718010" mdrpt="haemorrhagic stroke">hemorrhagic stroke</span> was similar between groups (17 LIPITOR vs. 18 placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes). Subjects who entered the study with a <span class="conditions" mdrptid="36718010" mdrpt="haemorrhagic stroke">hemorrhagic stroke</span> appeared to be at increased risk for <span class="conditions" mdrptid="36718010" mdrpt="haemorrhagic stroke">hemorrhagic stroke</span> [7 (16%) LIPITOR vs. 2 (4%) placebo].</p>
                    <p>There were no significant differences between the treatment groups for all-cause mortality: 216 (9.1%) in the LIPITOR 80 mg/day group vs. 211 (8.9%) in the placebo group. The proportions of subjects who experienced cardiovascular <span class="conditions" mdrptid="35809059" mdrpt="death">death</span> were numerically smaller in the LIPITOR 80 mg group (3.3%) than in the placebo group (4.1%). The proportions of subjects who experienced non-cardiovascular <span class="conditions" mdrptid="35809059" mdrpt="death">death</span> were numerically larger in the LIPITOR 80 mg group (5.0%) than in the placebo group (4.0%).</p>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S6.2"></a><a name="section-6.2"></a><p></p>
                <h2>6.2	Postmarketing Experience</h2>
                <p class="First">The following adverse reactions have been identified during postapproval use of LIPITOR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
                <p>Adverse reactions associated with LIPITOR therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: <span class="conditions" mdrptid="36009756" mdrpt="anaphylactic reaction">anaphylaxis</span>, <span class="conditions" mdrptid="36009762" mdrpt="angioedema">angioneurotic edema</span>, bullous rashes (including <span class="conditions" mdrptid="36009707" mdrpt="erythema multiforme">erythema multiforme</span>, <span class="conditions" mdrptid="36009724" mdrpt="stevens-johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="conditions" mdrptid="36009754" mdrpt="toxic epidermal necrolysis">toxic epidermal necrolysis</span>), <span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">rhabdomyolysis</span>, <span class="conditions" mdrptid="35809076" mdrpt="fatigue">fatigue</span>, <span class="conditions" mdrptid="36211268" mdrpt="tendon rupture">tendon rupture</span>, fatal and non-fatal <span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">hepatic failure</span>, <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span>, <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span>, peripheral <span class="conditions" mdrptid="36718500" mdrpt="neuropathy peripheral">neuropathy</span>, and <span class="conditions" mdrptid="35707713" mdrpt="pancreatitis">pancreatitis</span>.</p>
                <p>There have been rare reports of immune-mediated necrotizing <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> associated with statin use [see <span class="Italics">Warnings and Precautions (<a href="#S5.1">5.1</a>)</span>].</p>
                <p>There have been rare postmarketing reports of <span class="conditions" mdrptid="36718179" mdrpt="cognitive disorder">cognitive impairment</span> (e.g., <span class="conditions" mdrptid="36718171" mdrpt="amnesia">memory loss</span>, <span class="conditions" mdrptid="36718175" mdrpt="memory impairment">forgetfulness</span>, <span class="conditions" mdrptid="36718171" mdrpt="amnesia">amnesia</span>, <span class="conditions" mdrptid="36718175" mdrpt="memory impairment">memory impairment</span>, <span class="conditions" mdrptid="36718301" mdrpt="confusional state">confusion</span>) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S6.3"></a><a name="section-6.3"></a><p></p>
                <h2>6.3	Pediatric Patients (ages 10–17 years)</h2>
                <p class="First">In a 26-week controlled study in boys and postmenarchal girls (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of LIPITOR 10 to 20 mg daily was generally similar to that of placebo [see <span class="Italics"><a href="#s14.6">Clinical Studies (14.6)</a></span> and <span class="Italics"><a href="#S8.4">Use in Special Populations, Pediatric Use (8.4)</a></span>].</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34073-7">
            <a name="S7"></a><a name="section-7"></a><p></p>
            <h1>7 DRUG INTERACTIONS</h1>
            <p class="First">The risk of <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see <span class="Italics"><a href="#s5.1">Warnings and Precautions, Skeletal Muscle (5.1) </a></span>and <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S7.1"></a><a name="section-7.1"></a><p></p>
                <h2>7.1  Strong Inhibitors of CYP 3A4</h2>
                <p class="First">LIPITOR is metabolized by cytochrome P450 3A4. Concomitant administration of LIPITOR with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin. The extent of <span class="conditions" mdrptid="35809310" mdrpt="drug interaction">interaction</span> and potentiation of effects depend on the variability of effect on CYP 3A4.</p>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-7.1.1"></a><p></p>
                    <dl>
                        <dt> </dt>
                        <dd>
                            <span class="Bold">  Clarithromycin: </span>Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see <span class="Italics"><a href="#S5.1">Warnings and Precautions, Skeletal Muscle (5.1)</a></span> and <span class="Italics"><a href="#S2.6">Dosage and Administration (2.6)</a></span>].
                        </dd>
                    </dl>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-7.1.2"></a><p></p>
                    <dl>
                        <dt> </dt>
                        <dd>
                            <span class="Bold">Combination of Protease Inhibitors:</span> Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR with several combinations of HIV protease inhibitors, as well as with the <span class="conditions" mdrptid="35909578" mdrpt="hepatitis c">hepatitis C</span> protease inhibitor telaprevir,  compared to that of LIPITOR alone [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the <span class="conditions" mdrptid="35909578" mdrpt="hepatitis c">hepatitis C</span> protease inhibitor telaprevir, concomitant use of LIPITOR should be avoided. In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing LIPITOR and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of LIPITOR should not exceed 20 mg and should be used with caution [see <span class="Italics"><a href="#s5.1">Warnings and Precautions, Skeletal Muscle (5.1)</a></span> and <span class="Italics"><a href="#S2.6">Dosage and Administration (2.6)</a></span>].  In patients taking the HIV protease inhibitor nelfinavir or the <span class="conditions" mdrptid="35909578" mdrpt="hepatitis c">hepatitis C</span> protease inhibitor boceprevir, the dose of LIPITOR should not exceed 40 mg and close clinical monitoring is recommended.
                        </dd>
                    </dl>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-7.1.3"></a><p></p>
                    <dl>
                        <dt> </dt>
                        <dd>
                            <span class="Bold">Itraconazole:</span> Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg [see <span class="Italics"><a href="#S5.1">Warnings and Precautions, Skeletal Muscle (5.1)</a></span> and <span class="Italics"><a href="#S2.6">Dosage and Administration (2.6)</a></span>].
                        </dd>
                    </dl>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S7.2"></a><a name="section-7.2"></a><p></p>
                <h2>7.2  Grapefruit Juice</h2>
                <p class="First">Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 liters per day).</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S7.3"></a><a name="section-7.3"></a><p></p>
                <h2>7.3  Cyclosporine</h2>
                <p class="First">Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. The co-administration of LIPITOR with cyclosporine should be avoided [see <span class="Italics"><a href="#S5.1">Warnings and Precautions, Skeletal Muscle (5.1)</a></span>].</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S7.4"></a><a name="section-7.4"></a><p></p>
                <h2>7.4 Gemfibrozil</h2>
                <p class="First">Due to an increased risk of <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span>/<span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">rhabdomyolysis</span> when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, concomitant administration of LIPITOR with gemfibrozil should be avoided [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S7.5"></a><a name="section-7.5"></a><p></p>
                <h2>7.5 Other Fibrates</h2>
                <p class="First">Because it is known that the risk of <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, LIPITOR should be administered with caution when used concomitantly with other fibrates [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S7.6"></a><a name="section-7.6"></a><p></p>
                <h2>7.6 Niacin</h2>
                <p class="First">The risk of skeletal muscle effects may be enhanced when LIPITOR is used in combination with niacin; a reduction in LIPITOR dosage should be considered in this setting [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S7.7"></a><a name="section-7.7"></a><p></p>
                <h2>7.7  Rifampin or other Inducers of Cytochrome P450 3A4</h2>
                <p class="First">Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual <span class="conditions" mdrptid="35809310" mdrpt="drug interaction">interaction</span> mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S7.8"></a><a name="section-7.8"></a><p></p>
                <h2>7.8  Digoxin</h2>
                <p class="First">When multiple doses of LIPITOR and digoxin were co-administered, steady state plasma digoxin concentrations increased by approximately 20%. Patients taking digoxin should be monitored appropriately.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S7.9"></a><a name="section-7.9"></a><p></p>
                <h2>7.9 Oral Contraceptives</h2>
                <p class="First">Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. These increases should be considered when selecting an oral contraceptive for a woman taking LIPITOR.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S7.10"></a><a name="section-7.10"></a><p></p>
                <h2>7.10  Warfarin</h2>
                <p class="First">LIPITOR had no clinically significant effect on <span class="conditions" mdrptid="36313088" mdrpt="prothrombin time">prothrombin time</span> when administered to patients receiving chronic warfarin treatment.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S7.11"></a><a name="section-7.11"></a><p></p>
                <h2>7.11 Colchicine</h2>
                <p class="First">Cases of <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span>, including <span class="conditions" mdrptid="36516888" mdrpt="rhabdomyolysis">rhabdomyolysis</span>, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="43684-0">
            <a name="S8"></a><a name="section-8"></a><p></p>
            <h1>8 USE IN SPECIFIC POPULATIONS</h1>
            <div class="Section" data-sectionCode="42228-7">
                <a name="S8.1"></a><a name="section-8.1"></a><p></p>
                <h2>8.1  <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span></h2>
                <div class="Section" data-sectionCode="34077-8">
                    <a name="section-8.1.1"></a><p></p>
                    <p class="First"><span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> Category X</p>
                    <p>LIPITOR is contraindicated in women who are or may become <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span>. <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">Serum cholesterol</span> and <span class="conditions" mdrptid="36314070" mdrpt="blood triglycerides">triglycerides</span> increase during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">normal pregnancy</span>. Lipid lowering drugs offer no benefit during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> because <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> and <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> derivatives are needed for normal fetal development. <span class="conditions" mdrptid="37622403" mdrpt="arteriosclerosis">Atherosclerosis</span> is a chronic process, and discontinuation of lipid-lowering drugs during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> should have little impact on long-term outcomes of primary <span class="conditions" mdrptid="36416634" mdrpt="hypercholesterolaemia">hypercholesterolemia</span> therapy. </p>
                    <p>There are no adequate and well-controlled studies of atorvastatin use during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span>. There have been rare reports of <span class="conditions" mdrptid="35305493" mdrpt="congenital anomaly">congenital</span> anomalies following intrauterine exposure to statins. In a review of about 100 prospectively followed pregnancies in women exposed to other statins, the incidences of <span class="conditions" mdrptid="35305493" mdrpt="congenital anomaly">congenital</span> anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed the rate expected in the general population. However, this study was only able to exclude a three-to-four-fold increased risk of <span class="conditions" mdrptid="35305493" mdrpt="congenital anomaly">congenital</span> anomalies over background incidence. In 89% of these cases, drug treatment started before <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> and stopped during the first trimester when <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> was identified.</p>
                    <p>Atorvastatin crosses the rat placenta and reaches a level in fetal liver equivalent to that of maternal plasma. Atorvastatin was not teratogenic in rats at doses up to 300 mg/kg/day or in rabbits at doses up to 100 mg/kg/day. These doses resulted in multiples of about 30 times (rat) or 20 times (rabbit) the human exposure based on surface area (mg/m<span class="Sup">2</span>) [see <span class="Italics"><a href="#S4.3">Contraindications, <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> (4.3)</a></span>].</p>
                    <p>In a study in rats given 20, 100, or 225 mg/kg/day, from gestation day 7 through to lactation day 21 (weaning), there was decreased pup survival at birth, <span class="conditions" mdrptid="37420351" mdrpt="infant">neonate</span>, weaning, and maturity in pups of mothers dosed with 225 mg/kg/day. Body weight was decreased on days 4 and 21 in pups of mothers dosed at 100 mg/kg/day; pup body weight was decreased at birth and at days 4, 21, and 91 at 225 mg/kg/day. Pup development was delayed (rotorod performance at 100 mg/kg/day and acoustic startle at 225 mg/kg/day; pinnae <span class="conditions" mdrptid="36918962" mdrpt="dissociation">detachment</span> and eye-opening at 225 mg/kg/day). These doses correspond to 6 times (100 mg/kg) and 22 times (225 mg/kg) the human AUC at 80 mg/day. </p>
                    <p>Statins may cause fetal harm when administered to a <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> woman. LIPITOR should be administered to women of childbearing potential only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If the woman becomes <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> while taking LIPITOR, it should be discontinued immediately and the patient advised again as to the potential hazards to the fetus and the lack of known clinical benefit with continued use during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span>.</p>
                </div>
            </div>
            <div class="Section" data-sectionCode="34080-2">
                <a name="S8.3"></a><a name="section-8.2"></a><p></p>
                <h2>8.3  Nursing Mothers</h2>
                <p class="First">It is not known whether atorvastatin is excreted in human milk, but a small amount of another drug in this class does pass into breast milk. Nursing rat pups had plasma and liver drug levels of 50% and 40%, respectively, of that in their mother's milk. Animal breast milk drug levels may not accurately reflect human breast milk levels. Because another drug in this class passes into human milk and because statins have a potential to cause serious adverse reactions in nursing infants, women requiring LIPITOR treatment should be advised not to nurse their infants [see <span class="Italics"><a href="#S4"> Contraindications (4)</a></span>].</p>
            </div>
            <div class="Section" data-sectionCode="34081-0">
                <a name="S8.4"></a><a name="section-8.3"></a><p></p>
                <h2>8.4  Pediatric Use</h2>
                <p class="First">Safety and effectiveness in patients 10–17 years of age with <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">heterozygous familial hypercholesterolemia</span> have been evaluated in a controlled clinical trial of 6 months' duration in adolescent boys and postmenarchal girls. Patients treated with LIPITOR had an adverse experience profile generally similar to that of patients treated with placebo. The most common adverse experiences observed in both groups, regardless of causality assessment, were infections. <span class="Bold">Doses greater than 20 mg have not been studied in this patient population.</span> In this limited controlled study, there was no significant effect on growth or sexual maturation in boys or on menstrual cycle length in girls [see <span class="Italics"><a href="#S14.6">Clinical Studies (14.6)</a>; <a href="#S6.3">Adverse Reactions, Pediatric Patients (ages 10–17 years) (6.3)</a></span>; and <span class="Italics"><a href="#S2.2">Dosage and Administration, <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients (10–17 years of age) (2.2)</a></span>]. Adolescent females should be counseled on appropriate contraceptive methods while on LIPITOR therapy [see <span class="Italics"><a href="#S4.3">Contraindications, <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> (4.3) </a></span>and <span class="Italics"><a href="#S8.1">Use in Specific Populations, <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> (8.1)</a></span>]. <span class="Bold">LIPITOR has not been studied in controlled clinical trials involving pre-pubertal patients or patients younger than 10 years of age.</span></p>
                <p>Clinical efficacy with doses up to 80 mg/day for 1 year have been evaluated in an uncontrolled study of patients with homozygous FH including 8 pediatric patients [see <span class="Italics"><a href="#s14.5">Clinical Studies, <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">Homozygous Familial Hypercholesterolemia</span> (14.5)</a></span>].</p>
            </div>
            <div class="Section" data-sectionCode="34082-8">
                <a name="S8.5"></a><a name="section-8.4"></a><p></p>
                <h2>8.5  Geriatric Use</h2>
                <p class="First">Of the 39,828 patients who received LIPITOR in clinical studies, 15,813 (40%) were ≥65 years old and 2,800 (7%) were ≥75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span> and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (≥65 years) is a predisposing factor for <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span>, LIPITOR should be prescribed with caution in the <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span>. </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S8.6"></a><a name="section-8.5"></a><p></p>
                <h2>8.6	<span class="conditions" mdrptid="35909501" mdrpt="liver disorder">Hepatic Impairment</span></h2>
                <p class="First">Lipitor is contraindicated in patients with active liver disease which may include unexplained persistent elevations in hepatic transaminase levels [see <span class="Italics"><a href="#s4">Contraindications (4)</a></span> and <span class="Italics"><a href="#S12.3">Pharmacokinetics (12.3)</a></span>].</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34088-5">
            <a name="S10"></a><a name="section-9"></a><p></p>
            <h1>10	OVERDOSAGE</h1>
            <p class="First">There is no specific treatment for LIPITOR overdosage. In the event of an <span class="conditions" mdrptid="36211496" mdrpt="overdose">overdose</span>, the patient should be treated symptomatically, and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, <span class="conditions" mdrptid="37521163" mdrpt="haemodialysis">hemodialysis</span> is not expected to significantly enhance LIPITOR clearance.</p>
        </div>
        <div class="Section" data-sectionCode="34089-3">
            <a name="S11"></a><a name="section-10"></a><p></p>
            <h1>11	DESCRIPTION</h1>
            <p class="First">LIPITOR is a synthetic lipid-lowering agent. Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> biosynthesis.</p>
            <p>Atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> is [R-(R*, R*)]-2-(4-fluorophenyl)-ß, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> salt (2:1) trihydrate. The empirical formula of atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> is (C<span class="Sub">33</span>H<span class="Sub">34 </span>FN<span class="Sub">2</span>O<span class="Sub">5</span>)<span class="Sub">2</span>Ca•3H<span class="Sub">2</span>O and its molecular weight is 1209.42. Its structural formula is:</p>
            <p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-01.jpg"></p>
            <p>Atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> is a white to off-white crystalline powder that is insoluble in aqueous solutions of pH 4 and below. Atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> is very slightly soluble in distilled water, pH 7.4 <span class="conditions" mdrptid="36316374" mdrpt="blood phosphorus">phosphate</span> buffer, and acetonitrile; slightly soluble in ethanol; and freely soluble in methanol.</p>
            <p>LIPITOR Tablets for oral administration contain 10, 20, 40, or 80 mg atorvastatin and the following inactive ingredients: <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> carbonate, USP; candelilla wax, FCC; croscarmellose <span class="conditions" mdrptid="36316389" mdrpt="blood sodium">sodium</span>, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS-1-7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.</p>
        </div>
        <div class="Section" data-sectionCode="34090-1">
            <a name="S12"></a><a name="section-11"></a><p></p>
            <h1>12   CLINICAL PHARMACOLOGY</h1>
            <div class="Section" data-sectionCode="43679-0">
                <a name="S12.1"></a><a name="section-11.1"></a><p></p>
                <h2>12.1  Mechanism of Action</h2>
                <p class="First">LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span>. <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">Cholesterol</span> and <span class="conditions" mdrptid="36314070" mdrpt="blood triglycerides">triglycerides</span> circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. <span class="conditions" mdrptid="36314070" mdrpt="blood triglycerides">Triglycerides</span> (TG) and <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> in the liver are incorporated into VLDL and released into the plasma for <span class="conditions" mdrptid="36818826" mdrpt="delivery">delivery</span> to peripheral tissues. <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> is formed from VLDL and is catabolized primarily through the high-affinity <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> receptor. Clinical and pathologic studies show that elevated plasma levels of total <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> (total-C), <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-<span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> (<span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C), and apolipoprotein B (apo B) promote human <span class="conditions" mdrptid="37622403" mdrpt="arteriosclerosis">atherosclerosis</span> and are risk factors for developing cardiovascular disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk.</p>
                <p>In animal models, LIPITOR lowers <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">plasma cholesterol</span> and lipoprotein levels by inhibiting HMG-CoA reductase and <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> synthesis in the liver and by increasing the number of hepatic <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> receptors on the cell surface to enhance uptake and catabolism of <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>; LIPITOR also reduces <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> production and the number of <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> particles. LIPITOR reduces <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C in some patients with <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">homozygous familial hypercholesterolemia</span> (FH), a population that rarely responds to other lipid-lowering medication(s).</p>
                <p>A variety of clinical studies have demonstrated that elevated levels of total-C, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, and apo B (a membrane complex for <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C) promote human <span class="conditions" mdrptid="37622403" mdrpt="arteriosclerosis">atherosclerosis</span>. Similarly, decreased levels of HDL-C (and its transport complex, apo A) are associated with the development of <span class="conditions" mdrptid="37622403" mdrpt="arteriosclerosis">atherosclerosis</span>. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C and <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, and inversely with the level of HDL-C.</p>
                <p>LIPITOR reduces total-C, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, and apo B in patients with homozygous and heterozygous FH, nonfamilial forms of <span class="conditions" mdrptid="36416634" mdrpt="hypercholesterolaemia">hypercholesterolemia</span>, and mixed <span class="conditions" mdrptid="36416641" mdrpt="dyslipidaemia">dyslipidemia</span>. LIPITOR also reduces VLDL-C and TG and produces variable increases in HDL-C and apolipoprotein A-1. LIPITOR reduces total-C, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, VLDL-C, apo B, TG, and non-HDL-C, and increases HDL-C in patients with isolated <span class="conditions" mdrptid="36416637" mdrpt="hypertriglyceridaemia">hypertriglyceridemia</span>. LIPITOR reduces intermediate density lipoprotein <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> (IDL-C) in patients with dysbetalipoproteinemia. </p>
                <p>Like <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>, <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span>-enriched triglyceride-rich lipoproteins, including VLDL, intermediate density lipoprotein (IDL), and remnants, can also promote <span class="conditions" mdrptid="37622403" mdrpt="arteriosclerosis">atherosclerosis</span>. Elevated <span class="conditions" mdrptid="36314070" mdrpt="blood triglycerides">plasma triglycerides</span> are frequently found in a triad with <span class="conditions" mdrptid="36313993" mdrpt="high density lipoprotein decreased">low HDL</span>-C levels and small <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> particles, as well as in association with non-lipid metabolic risk factors for <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary heart disease</span>. As such, total plasma TG has not consistently been shown to be an independent risk factor for CHD. Furthermore, the independent effect of raising HDL or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.</p>
            </div>
            <div class="Section" data-sectionCode="43681-6">
                <a name="S12.2"></a><a name="section-11.2"></a><p></p>
                <h2>12.2	Pharmacodynamics</h2>
                <p class="First">LIPITOR, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> synthesis and <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> clearance. Drug dosage, rather than systemic drug concentration, correlates better with <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C reduction. Individualization of drug dosage should be based on therapeutic response [see<span class="Italics"><a href="#S2"> Dosage and Administration (2)</a></span>].</p>
            </div>
            <div class="Section" data-sectionCode="43682-4">
                <a name="S12.3"></a><a name="section-11.3"></a><p></p>
                <h2>12.3	Pharmacokinetics</h2>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-11.3.1"></a><p></p>
                    <p class="First"><span class="Bold">Absorption: </span>LIPITOR is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to LIPITOR dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C reduction is similar whether LIPITOR is given with or without food. Plasma LIPITOR concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C reduction is the same regardless of the time of day of drug administration [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span>].</p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-11.3.2"></a><p></p>
                    <p class="First"><span class="Bold">Distribution: </span>Mean volume of distribution of LIPITOR is approximately 381 liters. LIPITOR is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, LIPITOR is likely to be secreted in human milk [see <span class="Italics"><a href="#S4.4">Contraindications, Nursing Mothers (4.4) </a></span>and <span class="Italics"><a href="#S8.3">Use in Specific Populations, Nursing Mothers (8.3)</a></span>].</p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-11.3.3"></a><p></p>
                    <p class="First"><span class="Bold">Metabolism: </span>LIPITOR is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. <span class="Italics">In vitro </span>inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of LIPITOR. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. <span class="Italics">In vitro </span>studies suggest the importance of LIPITOR metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of LIPITOR in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see <span class="Italics"><a href="#S7.1">Drug Interactions (7.1)</a></span>]. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.</p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-11.3.4"></a><p></p>
                    <p class="First"><span class="Bold">Excretion: </span>LIPITOR and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of LIPITOR in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of LIPITOR is recovered in urine following oral administration.</p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="section-11.3.5"></a><p></p>
                    <p class="First"><span class="Bold">Specific Populations</span></p>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="section-11.3.5.1"></a><p></p>
                        <p class="First"><span class="Bold">Geriatric: </span>Plasma concentrations of LIPITOR are higher (approximately 40% for Cmax and 30% for AUC) in healthy <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span> subjects (age ≥65 years) than in young adults. Clinical data suggest a greater degree of <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-lowering at any dose of drug in the <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span> patient population compared to younger adults [see <span class="Italics"><a href="#S8.5">Use in Specific Populations, Geriatric Use (8.5)</a></span>].</p>
                    </div>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="section-11.3.5.2"></a><p></p>
                        <p class="First"><span class="Bold">Pediatric: </span>Pharmacokinetic data in the pediatric population are not available.</p>
                    </div>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="section-11.3.5.3"></a><p></p>
                        <p class="First"><span class="Bold">Gender: </span>Plasma concentrations of LIPITOR in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C reduction with LIPITOR between men and women.</p>
                    </div>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="section-11.3.5.4"></a><p></p>
                        <p class="First"><span class="Bold"><span class="conditions" mdrptid="37019321" mdrpt="renal impairment">Renal Impairment</span>:</span> <span class="conditions" mdrptid="37019308" mdrpt="renal disorder">Renal disease</span> has no influence on the plasma concentrations or <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C reduction of LIPITOR; thus, dose adjustment in patients with renal dysfunction is not necessary [see<span class="Italics"><a href="#S2.5"> Dosage and Administration, Dosage in Patients with <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">Renal Impairment</span> (2.5)</a></span>,<span class="Italics"><a href="#s5.1"> Warnings and Precautions, Skeletal Muscle (5.1)</a></span>].</p>
                    </div>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="section-11.3.5.5"></a><p></p>
                        <p class="First"><span class="Bold"><span class="conditions" mdrptid="37521163" mdrpt="haemodialysis">Hemodialysis</span>: </span>While studies have not been conducted in patients with end-stage <span class="conditions" mdrptid="37019308" mdrpt="renal disorder">renal disease</span>, <span class="conditions" mdrptid="37521163" mdrpt="haemodialysis">hemodialysis</span> is not expected to significantly enhance clearance of LIPITOR since the drug is extensively bound to plasma proteins.</p>
                    </div>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="section-11.3.5.6"></a><p></p>
                        <p class="First"><span class="Bold"><span class="conditions" mdrptid="35909501" mdrpt="liver disorder">Hepatic Impairment</span>: </span>In patients with chronic <span class="conditions" mdrptid="35909604" mdrpt="alcoholic liver disease">alcoholic liver disease</span>, plasma concentrations of LIPITOR are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see<span class="Italics"><a href="#S4.1"> Contraindications (4.1)</a></span>].</p>
                        <a name="table3"></a><table width="100%">
                            <caption><span>TABLE 3. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin</span></caption>
                            <col align="left" valign="middle" width="40%">
                            <col align="left" valign="middle" width="30%">
                            <col align="left" valign="middle" width="15%">
                            <col align="left" valign="middle" width="15%">
                            <thead>
                                <tr class="Botrule First">
                                    <th class="Lrule Rrule" align="center">Co-administered drug and dosing regimen</th>
                                    <th class="Rrule" align="center" colspan="3" valign="top">Atorvastatin</th>
                                </tr>
                                <tr class="Last">
                                    <th class="Lrule Rrule" align="left"></th>
                                    <th class="Rrule" align="left" valign="top">Dose (mg)</th>
                                    <th class="Rrule" align="left">
                                        Change  in AUC<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
                                    </th>
                                    <th class="Rrule" align="left">
                                        Change in Cmax<a href="#footnote-3" class="Sup">*</a>
                                    </th>
                                </tr>
                            </thead>
                            <tfoot>
                                <tr>
                                    <td colspan="4" align="left">
                                        <dl class="Footnote">
                                            <dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
                                            <dd> Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1-fold = no change). Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change).</dd>
                                            <dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
                                            <dd>See Sections <a href="#S5.1">5.1</a> and <a href="#S7">7</a> for clinical significance.</dd>
                                            <dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
                                            <dd>The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used.</dd>
                                            <dt><a name="footnote-6" href="#footnote-reference-6">§</a></dt>
                                            <dd>Greater increases in AUC (up to 2.5 fold) and/or Cmax (up to 71%) have been reported with excessive grapefruit consumption (≥ 750 mL – 1.2 liters per day).</dd>
                                            <dt><a name="footnote-7" href="#footnote-reference-7">¶</a></dt>
                                            <dd>Single sample taken 8–16 h post dose.</dd>
                                            <dt><a name="footnote-8" href="#footnote-reference-8">#</a></dt>
                                            <dd>Due to the dual <span class="conditions" mdrptid="35809310" mdrpt="drug interaction">interaction</span> mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.</dd>
                                        </dl>
                                    </td>
                                </tr>
                            </tfoot>
                            <tbody>
                                <tr class="Botrule First">
                                    <td class="Lrule Rrule" align="left">
                                        <a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>Cyclosporine 5.2 mg/kg/day, stable dose
                                    </td>
                                    <td class="Rrule" align="left">10 mg QD for 28 days</td>
                                    <td class="Rrule" align="left">↑ 8.7 fold</td>
                                    <td class="Rrule" align="left">↑ 10.7 fold</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days
                                    </td>
                                    <td class="Rrule" align="left">10 mg, SD</td>
                                    <td class="Rrule" align="left">↑ 9.4 fold</td>
                                    <td class="Rrule" align="left">↑ 8.6 fold</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Telaprevir 750 mg q8h, 10 days
                                    </td>
                                    <td class="Rrule" align="left">20 mg, SD</td>
                                    <td class="Rrule" align="left">↑ 7.88 fold</td>
                                    <td class="Rrule" align="left">↑ 10.6 fold</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a><span class="Sup">, </span><a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a>Saquinavir 400 mg BID/ ritonavir 400mg BID, 15 days
                                    </td>
                                    <td class="Rrule" align="left">40 mg QD for 4 days</td>
                                    <td class="Rrule" align="left">↑ 3.9 fold</td>
                                    <td class="Rrule" align="left">↑ 4.3 fold</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Clarithromycin 500 mg BID, 9 days
                                    </td>
                                    <td class="Rrule" align="left">80 mg QD for 8 days</td>
                                    <td class="Rrule" align="left">↑ 4.4 fold</td>
                                    <td class="Rrule" align="left">↑ 5.4 fold</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days
                                    </td>
                                    <td class="Rrule" align="left">10 mg QD for 4 days</td>
                                    <td class="Rrule" align="left">↑ 3.4 fold</td>
                                    <td class="Rrule" align="left">↑ 2.25 fold</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Itraconazole 200 mg QD, 4 days
                                    </td>
                                    <td class="Rrule" align="left">40 mg SD</td>
                                    <td class="Rrule" align="left">↑ 3.3 fold</td>
                                    <td class="Rrule" align="left">↑ 20%  </td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days
                                    </td>
                                    <td class="Rrule" align="left">10 mg QD for 4 days</td>
                                    <td class="Rrule" align="left">↑ 2.53 fold</td>
                                    <td class="Rrule" align="left">↑ 2.84 fold</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Fosamprenavir 1400 mg BID, 14 days
                                    </td>
                                    <td class="Rrule" align="left">10 mg QD for 4 days</td>
                                    <td class="Rrule" align="left">↑ 2.3 fold</td>
                                    <td class="Rrule" align="left">↑ 4.04 fold</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Nelfinavir 1250 mg BID, 14 days
                                    </td>
                                    <td class="Rrule" align="left">10 mg QD for 28 days</td>
                                    <td class="Rrule" align="left">↑ 74%</td>
                                    <td class="Rrule" align="left">↑ 2.2 fold</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Grapefruit Juice, 240 mL QD <a name="footnote-reference-6" href="#footnote-6" class="Sup">§</a>
                                    </td>
                                    <td class="Rrule" align="left">40 mg, SD</td>
                                    <td class="Rrule" align="left">↑ 37%</td>
                                    <td class="Rrule" align="left">↑ 16%</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">Diltiazem 240 mg QD, 28 days </td>
                                    <td class="Rrule" align="left">40 mg, SD</td>
                                    <td class="Rrule" align="left">↑ 51%</td>
                                    <td class="Rrule" align="left">No change</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">Erythromycin 500 mg QID, 7 days </td>
                                    <td class="Rrule" align="left">10 mg, SD</td>
                                    <td class="Rrule" align="left">↑ 33%</td>
                                    <td class="Rrule" align="left">↑ 38%</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">Amlodipine 10 mg, single dose </td>
                                    <td class="Rrule" align="left">80 mg, SD</td>
                                    <td class="Rrule" align="left">↑ 15%</td>
                                    <td class="Rrule" align="left">↓ 12 %</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">Cimetidine 300 mg QID, 2 weeks </td>
                                    <td class="Rrule" align="left">10 mg QD for 2 weeks</td>
                                    <td class="Rrule" align="left">↓ Less than 1%</td>
                                    <td class="Rrule" align="left">↓ 11%</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">Colestipol 10 mg BID, 28 weeks </td>
                                    <td class="Rrule" align="left">40 mg QD for 28 weeks</td>
                                    <td class="Rrule" align="left">Not determined</td>
                                    <td class="Rrule" align="left">
                                        ↓ 26%<a name="footnote-reference-7" href="#footnote-7" class="Sup">¶</a>
                                    </td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">Maalox TC® 30 mL QD, 17 days </td>
                                    <td class="Rrule" align="left">10 mg QD for 15 days</td>
                                    <td class="Rrule" align="left">↓ 33%</td>
                                    <td class="Rrule" align="left">↓ 34%</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">Efavirenz 600 mg QD, 14 days </td>
                                    <td class="Rrule" align="left">10 mg for 3 days</td>
                                    <td class="Rrule" align="left">↓ 41%</td>
                                    <td class="Rrule" align="left">↓ 1%</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Rifampin 600 mg QD, 7 days (co-administered) <a name="footnote-reference-8" href="#footnote-8" class="Sup">#</a>
                                    </td>
                                    <td class="Rrule" align="left">40 mg SD</td>
                                    <td class="Rrule" align="left">↑ 30%</td>
                                    <td class="Rrule" align="left">↑ 2.7 fold</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Rifampin 600 mg QD, 5 days (doses separated) <a href="#footnote-8" class="Sup">#</a>
                                    </td>
                                    <td class="Rrule" align="left">40 mg SD</td>
                                    <td class="Rrule" align="left">↓ 80%</td>
                                    <td class="Rrule" align="left">↓ 40%</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Gemfibrozil 600mg BID, 7 days
                                    </td>
                                    <td class="Rrule" align="left">40mg SD  </td>
                                    <td class="Rrule" align="left">↑ 35%</td>
                                    <td class="Rrule" align="left">↓ Less than 1%</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">
                                        <a href="#footnote-4" class="Sup">†</a>Fenofibrate 160mg QD, 7 days
                                    </td>
                                    <td class="Rrule" align="left">40mg SD       </td>
                                    <td class="Rrule" align="left">↑ 3%</td>
                                    <td class="Rrule" align="left">↑ 2%</td>
                                </tr>
                                <tr class="Last">
                                    <td class="Lrule Rrule" align="left">Boceprevir 800 mg TID, 7 days</td>
                                    <td class="Rrule" align="left">40 mg SD</td>
                                    <td class="Rrule" align="left">↑2.30 fold</td>
                                    <td class="Rrule" align="left">↑2.66 fold</td>
                                </tr>
                            </tbody>
                        </table>
                        <a name="table4"></a><table width="100%">
                            <caption><span>TABLE 4. Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs</span></caption>
                            <col align="left" valign="top" width="25%">
                            <col align="left" valign="top" width="25%">
                            <col align="left" valign="top" width="25%">
                            <col align="left" valign="top" width="25%">
                            <thead>
                                <tr class="Botrule First">
                                    <th class="Lrule Rrule" align="center">Atorvastatin</th>
                                    <th class="Rrule" align="center" colspan="3">Co-administered drug and dosing regimen</th>
                                </tr>
                                <tr class="Last">
                                    <th class="Lrule Rrule" align="left"></th>
                                    <th class="Rrule" align="left">Drug/Dose (mg)</th>
                                    <th class="Rrule" align="left">Change  in AUC</th>
                                    <th class="Rrule" align="left">Change in Cmax</th>
                                </tr>
                            </thead>
                            <tfoot>
                                <tr>
                                    <td colspan="4" align="left">
                                        <dl class="Footnote">
                                            <dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
                                            <dd>See <a href="#S7">Section 7</a> for clinical significance.</dd>
                                        </dl>
                                    </td>
                                </tr>
                            </tfoot>
                            <tbody>
                                <tr class="Botrule First">
                                    <td class="Lrule Rrule" align="left">80 mg QD for 15 days </td>
                                    <td class="Rrule" align="left">Antipyrine, 600 mg SD</td>
                                    <td class="Rrule" align="left">↑ 3%</td>
                                    <td class="Rrule" align="left">↓ 11%</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">80 mg QD for 14 days</td>
                                    <td class="Rrule" align="left">
                                        <a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a> Digoxin 0.25 mg QD, 20 days
                                    </td>
                                    <td class="Rrule" align="left">↑ 15%</td>
                                    <td class="Rrule" align="left">↑ 20 %</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left">40 mg QD for 22 days </td>
                                    <td class="Rrule" align="left">Oral contraceptive QD,  2 months<br> - norethindrone 1mg<br> - ethinyl estradiol 35µg</td>
                                    <td class="Rrule" align="left" valign="bottom">
                                        <br> ↑ 28%<br> ↑ 19%
                                    </td>
                                    <td class="Rrule" align="left" valign="bottom">
                                        <br> ↑ 23%<br> ↑ 30%
                                    </td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left" valign="middle">10 mg, SD</td>
                                    <td class="Rrule" align="left" valign="middle">Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days</td>
                                    <td class="Rrule" align="left" valign="middle">No change</td>
                                    <td class="Rrule" align="left" valign="middle">No change</td>
                                </tr>
                                <tr class="Botrule">
                                    <td class="Lrule Rrule" align="left" valign="middle">10 mg QD for 4 days</td>
                                    <td class="Rrule" align="left" valign="middle">Fosamprenavir 1400 mg BID, 14 days</td>
                                    <td class="Rrule" align="left" valign="middle">↓ 27%</td>
                                    <td class="Rrule" align="left" valign="middle">↓ 18%</td>
                                </tr>
                                <tr class="Last">
                                    <td class="Lrule Rrule" align="left" valign="middle">10 mg QD for 4 days</td>
                                    <td class="Rrule" align="left" valign="middle">Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days</td>
                                    <td class="Rrule" align="left" valign="middle">No change</td>
                                    <td class="Rrule" align="left" valign="middle">No change</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>
        </div>
        <div class="Section" data-sectionCode="43680-8">
            <a name="S13"></a><a name="section-12"></a><p></p>
            <h1>13  NONCLINICAL TOXICOLOGY</h1>
            <div class="Section" data-sectionCode="34083-6">
                <a name="S13.1"></a><a name="section-12.1"></a><p></p>
                <h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
                <p class="First">In a 2-year <span class="conditions" mdrptid="36617300" mdrpt="neoplasm malignant">carcinogenicity</span> study in rats at dose levels of 10, 30, and 100 mg/kg/day, 2 rare tumors were found in muscle in high-dose females: in one, there was a <span class="conditions" mdrptid="36517095" mdrpt="rhabdomyosarcoma">rhabdomyosarcoma</span> and, in another, there was a <span class="conditions" mdrptid="36517051" mdrpt="fibrosarcoma">fibrosarcoma</span>. This dose represents a plasma AUC (0–24) value of approximately 16 times the mean human plasma drug exposure after an 80 mg oral dose.</p>
                <p>A 2-year <span class="conditions" mdrptid="36617300" mdrpt="neoplasm malignant">carcinogenicity</span> study in mice given 100, 200, or 400 mg/kg/day resulted in a significant increase in liver adenomas in high-dose males and liver carcinomas in high-dose females. These findings occurred at plasma AUC (0–24) values of approximately 6 times the mean human plasma drug exposure after an 80 mg oral dose.</p>
                <p><span class="Italics">In vitro,</span> atorvastatin was not mutagenic or clastogenic in the following tests with and without metabolic activation: the Ames test with <span class="Italics"><span class="conditions" mdrptid="36110212" mdrpt="salmonellosis">Salmonella</span> typhimurium </span>and <span class="Italics">Escherichia coli,</span> the HGPRT forward mutation assay in Chinese hamster lung cells, and the chromosomal aberration assay in Chinese hamster lung cells. Atorvastatin was negative in the <span class="Italics">in vivo </span>mouse micronucleus test.</p>
                <p>Studies in rats performed at doses up to 175 mg/kg (15 times the human exposure) produced no changes in fertility. There was <span class="conditions" mdrptid="35305490" mdrpt="aplasia">aplasia</span> and <span class="conditions" mdrptid="37119657" mdrpt="aspermia">aspermia</span> in the epididymis of 2 of 10 rats treated with 100 mg/kg/day of atorvastatin for 3 months (16 times the human AUC at the 80 mg dose); testis weights were significantly lower at 30 and 100 mg/kg and epididymal weight was lower at 100 mg/kg. Male rats given 100 mg/kg/day for 11 weeks prior to mating had decreased sperm motility, spermatid head concentration, and increased abnormal sperm. Atorvastatin caused no adverse effects on semen parameters, or reproductive organ histopathology in dogs given doses of 10, 40, or 120 mg/kg for two years.</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34092-7">
            <a name="S14"></a><a name="section-13"></a><p></p>
            <h1>14  CLINICAL STUDIES</h1>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S14.1"></a><a name="section-13.1"></a><p></p>
                <h2>14.1  <span class="conditions" mdrptid="37522077" mdrpt="prophylaxis">Prevention</span> of Cardiovascular Disease</h2>
                <p class="First">In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the effect of LIPITOR on fatal and non-fatal <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary heart disease</span> was assessed in 10,305 <span class="conditions" mdrptid="37622529" mdrpt="hypertension">hypertensive</span> patients 40–80 years of age (mean of 63 years), without a previous <span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">myocardial infarction</span> and with TC levels ≤251 mg/dL (6.5 mmol/L). Additionally, all patients had at least 3 of the following cardiovascular risk factors: male gender (81.1%), age &gt;55 years (84.5%), smoking (33.2%), <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span> (24.3%), history of CHD in a first-degree relative (26%), TC:HDL &gt;6 (14.3%), <span class="conditions" mdrptid="37622501" mdrpt="peripheral vascular disorder">peripheral vascular disease</span> (5.1%), <span class="conditions" mdrptid="35205325" mdrpt="left ventricular hypertrophy">left ventricular hypertrophy</span> (14.4%), prior cerebrovascular event (9.8%), specific <span class="conditions" mdrptid="36311902" mdrpt="electrocardiogram">ECG</span> abnormality (14.3%), <span class="conditions" mdrptid="37019440" mdrpt="proteinuria">proteinuria</span>/<span class="conditions" mdrptid="37019412" mdrpt="albuminuria">albuminuria</span> (62.4%). In this double-blind, placebo-controlled study, patients were treated with anti-<span class="conditions" mdrptid="37622529" mdrpt="hypertension">hypertensive</span> therapy (Goal BP &lt;140/90 mm Hg for non-<span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetic</span> patients; &lt;130/80 mm Hg for <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetic</span> patients) and allocated to either LIPITOR 10 mg daily (n=5168) or placebo (n=5137), using a covariate adaptive method which took into account the distribution of nine baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups. Patients were followed for a median duration of 3.3 years.</p>
                <p>The effect of 10 mg/day of LIPITOR on lipid levels was similar to that seen in previous clinical trials.</p>
                <p>LIPITOR significantly reduced the rate of coronary events [either fatal <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary heart disease</span> (46 events in the placebo group vs. 40 events in the LIPITOR group) or non-fatal MI (108 events in the placebo group vs. 60 events in the LIPITOR group)] with a relative risk reduction of 36% [(based on incidences of 1.9% for LIPITOR vs. 3.0% for placebo), p=0.0005 (see <a href="#figure1">Figure 1</a>)]. The risk reduction was consistent regardless of age, smoking status, <span class="conditions" mdrptid="36416534" mdrpt="obesity">obesity</span>, or presence of renal dysfunction. The effect of LIPITOR was seen regardless of baseline <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> levels. Due to the small number of events, results for women were inconclusive.</p>
                <p><span class="Bold">Figure 1: Effect of LIPITOR 10 mg/day on Cumulative Incidence of Non-Fatal <span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">Myocardial Infarction</span> or <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">Coronary Heart Disease</span> <span class="conditions" mdrptid="35809059" mdrpt="death">Death</span> (in ASCOT-LLA)</span></p>
                <p><a name="figure1"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-02.jpg"></p>
                <p>LIPITOR also significantly decreased the relative risk for revascularization procedures by 42%. Although the reduction of fatal and non-fatal strokes did not reach a pre-defined significance level (p=0.01), a favorable trend was observed with a 26% relative risk reduction (incidences of 1.7% for LIPITOR and 2.3% for placebo). There was no significant difference between the treatment groups for <span class="conditions" mdrptid="35809059" mdrpt="death">death</span> due to cardiovascular causes (p=0.51) or noncardiovascular causes (p=0.17).</p>
                <p>In the Collaborative Atorvastatin <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">Diabetes</span> Study (CARDS), the effect of LIPITOR on cardiovascular disease (CVD) endpoints was assessed in 2838 subjects (94% white, 68% male), ages 40–75 with type 2 <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span> based on WHO criteria, without prior history of cardiovascular disease and with <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span> ≤ 160 mg/dL and TG ≤ 600 mg/dL. In addition to <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span>, subjects had 1 or more of the following risk factors: current smoking (23%), <span class="conditions" mdrptid="37622529" mdrpt="hypertension">hypertension</span> (80%), <span class="conditions" mdrptid="35607430" mdrpt="retinopathy">retinopathy</span> (30%), or <span class="conditions" mdrptid="35506540" mdrpt="microalbuminuria">microalbuminuria</span> (9%) or macroalbuminuria (3%). No subjects on <span class="conditions" mdrptid="37521163" mdrpt="haemodialysis">hemodialysis</span> were enrolled in the study. In this multicenter, placebo-controlled, double-blind clinical trial, subjects were randomly allocated to either LIPITOR 10 mg daily (1429) or placebo (1411) in a 1:1 ratio and were followed for a median duration of 3.9 years. The primary endpoint was the occurrence of any of the major cardiovascular events: <span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">myocardial infarction</span>, acute CHD <span class="conditions" mdrptid="35809059" mdrpt="death">death</span>, <span class="conditions" mdrptid="35205182" mdrpt="angina unstable">unstable angina</span>, <span class="conditions" mdrptid="37522320" mdrpt="coronary revascularisation">coronary revascularization</span>, or <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span>. The primary analysis was the time to first occurrence of the primary endpoint. </p>
                <p>Baseline characteristics of subjects were: mean age of 62 years, mean HbA<span class="Sub">1c</span> 7.7%; median <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C 120 mg/dL; median TC 207   mg/dL; median TG 151 mg/dL; median HDL-C 52 mg/dL. </p>
                <p>The effect of LIPITOR 10 mg/day on lipid levels was similar to that seen in previous clinical trials. </p>
                <p>LIPITOR significantly reduced the rate of major cardiovascular events (primary endpoint events) (83 events in the LIPITOR group vs. 127 events in the placebo group) with a relative risk reduction of 37%, HR 0.63, 95% CI (0.48, 0.83) (p=0.001) (see <a href="#figure2">Figure 2</a>). An effect of LIPITOR was seen regardless of age, sex, or baseline lipid levels. </p>
                <p>LIPITOR significantly reduced the risk of <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span> by 48% (21 events in the LIPITOR group vs. 39 events in the placebo group), HR 0.52, 95% CI (0.31, 0.89) (p=0.016) and reduced the risk of MI by 42% (38 events in the LIPITOR group vs. 64 events in the placebo group), HR 0.58, 95.1% CI (0.39, 0.86) (p=0.007). There was no significant difference between the treatment groups for <span class="conditions" mdrptid="35205181" mdrpt="angina pectoris">angina</span>, revascularization procedures, and acute CHD <span class="conditions" mdrptid="35809059" mdrpt="death">death</span>.</p>
                <p>There were 61 deaths in the LIPITOR group vs. 82 deaths in the placebo group (HR 0.73, p=0.059).</p>
                <p><span class="Bold">Figure 2: Effect of LIPITOR 10 mg/day on Time to Occurrence of Major Cardiovascular Event (<span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">myocardial infarction</span>, acute CHD <span class="conditions" mdrptid="35809059" mdrpt="death">death</span>, <span class="conditions" mdrptid="35205182" mdrpt="angina unstable">unstable angina</span>, <span class="conditions" mdrptid="37522320" mdrpt="coronary revascularisation">coronary revascularization</span>, or <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span>) in CARDS</span></p>
                <p><a name="figure2"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-03.jpg"></p>
                <p>In the Treating to New Targets Study (TNT), the effect of LIPITOR 80 mg/day vs. LIPITOR 10 mg/day on the reduction in cardiovascular events was assessed in 10,001 subjects (94% white, 81% male, 38% ≥65 years) with clinically evident <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary heart disease</span> who had achieved a target <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C level &lt;130 mg/dL after completing an 8-week, open-label, run-in period with LIPITOR 10 mg/day. Subjects were randomly assigned to either 10 mg/day or 80 mg/day of LIPITOR and followed for a median duration of 4.9 years. The primary endpoint was the time-to-first occurrence of any of the following major cardiovascular events (MCVE): <span class="conditions" mdrptid="35809059" mdrpt="death">death</span> due to CHD, non-fatal <span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">myocardial infarction</span>, resuscitated <span class="conditions" mdrptid="35204966" mdrpt="cardiac arrest">cardiac arrest</span>, and fatal and non-fatal <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span>. The mean <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, TC, TG, non-HDL, and HDL <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> levels at 12 weeks were 73, 145, 128, 98, and 47 mg/dL during treatment with 80 mg of LIPITOR and 99, 177, 152, 129, and 48 mg/dL during treatment with 10 mg of LIPITOR.</p>
                <p>Treatment with LIPITOR 80 mg/day significantly reduced the rate of MCVE (434 events in the 80 mg/day group vs. 548 events in the 10 mg/day group) with a relative risk reduction of 22%, HR 0.78, 95% CI (0.69, 0.89), p=0.0002 (see <a href="#figure3">Figure 3</a> and <a href="#table5">Table 5</a>). The overall risk reduction was consistent regardless of age (&lt;65, ≥65) or gender. </p>
                <p><span class="Bold">Figure 3: Effect of LIPITOR 80 mg/day vs. 10 mg/day on Time to Occurrence of Major Cardiovascular Events (TNT)</span></p>
                <p><a name="figure3"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-04.jpg"></p>
                <a name="table5"></a><table width="100%">
                    <caption><span>TABLE 5. Overview of Efficacy Results in TNT</span></caption>
                    <col align="left" valign="top" width="40%">
                    <col align="center" valign="top" width="10%">
                    <col align="center" valign="top" width="10%">
                    <col align="center" valign="top" width="10%">
                    <col align="center" valign="top" width="10%">
                    <col align="center" valign="top" width="20%">
                    <thead>
                        <tr class="First Last">
                            <th class="Lrule Rrule" align="left">Endpoint</th>
                            <th class="Rrule" align="center" colspan="2">Atorvastatin<br>10 mg<br>(N=5006)</th>
                            <th class="Rrule" align="center" colspan="2">Atorvastatin<br>80 mg<br>(N=4995)</th>
                            <th class="Rrule" align="center" valign="middle">HR<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a> (95%CI)</th>
                        </tr>
                    </thead>
                    <tfoot>
                        <tr class="First Last"><td align="left" colspan="6">HR=hazard ratio; CHD=<span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary heart disease</span>; CI=confidence interval; MI=<span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">myocardial infarction</span>; <span class="conditions" mdrptid="35205243" mdrpt="cardiac failure congestive">CHF</span>=<span class="conditions" mdrptid="35205243" mdrpt="cardiac failure congestive">congestive heart failure</span>; CV=cardiovascular; PVD=<span class="conditions" mdrptid="37622501" mdrpt="peripheral vascular disorder">peripheral vascular disease</span>; <span class="conditions" mdrptid="37522318" mdrpt="coronary artery bypass">CABG</span>=<span class="conditions" mdrptid="37522318" mdrpt="coronary artery bypass">coronary artery bypass graft</span><br>Confidence intervals for the Secondary Endpoints were not adjusted for multiple comparisons </td></tr>
                        <tr>
                            <td colspan="6" align="left">
                                <dl class="Footnote">
                                    <dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
                                    <dd>Atorvastatin 80 mg: atorvastatin 10 mg</dd>
                                    <dt><a name="footnote-11" href="#footnote-reference-11">†</a></dt>
                                    <dd>Secondary endpoints not included in primary endpoint</dd>
                                    <dt><a name="footnote-12" href="#footnote-reference-12">‡</a></dt>
                                    <dd>Component of other secondary endpoints</dd>
                                </dl>
                            </td>
                        </tr>
                    </tfoot>
                    <tbody>
                        <tr class="Botrule First">
                            <td class="Lrule Rrule" align="left"><span class="Bold">PRIMARY ENDPOINT</span></td>
                            <td class="Rrule" align="center">n</td>
                            <td class="Rrule" align="center">(%)</td>
                            <td class="Rrule" align="center">n</td>
                            <td class="Rrule" align="center">(%)</td>
                            <td class="Rrule" align="center"></td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">First major cardiovascular endpoint</td>
                            <td class="Rrule" align="center">548</td>
                            <td class="Rrule" align="center">(10.9)</td>
                            <td class="Rrule" align="center">434</td>
                            <td class="Rrule" align="center">(8.7)</td>
                            <td class="Rrule" align="center">0.78 (0.69, 0.89)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left"><span class="Bold">Components of the Primary Endpoint</span></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">  CHD <span class="conditions" mdrptid="35809059" mdrpt="death">death</span></td>
                            <td class="Rrule" align="center">127</td>
                            <td class="Rrule" align="center">(2.5)</td>
                            <td class="Rrule" align="center">101</td>
                            <td class="Rrule" align="center">(2.0)</td>
                            <td class="Rrule" align="center">0.80 (0.61, 1.03)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">  Non-fatal, non-procedure related MI</td>
                            <td class="Rrule" align="center">308</td>
                            <td class="Rrule" align="center">(6.2)</td>
                            <td class="Rrule" align="center">243</td>
                            <td class="Rrule" align="center">(4.9)</td>
                            <td class="Rrule" align="center">0.78 (0.66, 0.93)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">  Resuscitated <span class="conditions" mdrptid="35204966" mdrpt="cardiac arrest">cardiac arrest</span></td>
                            <td class="Rrule" align="center">26</td>
                            <td class="Rrule" align="center">(0.5)</td>
                            <td class="Rrule" align="center">25</td>
                            <td class="Rrule" align="center">(0.5)</td>
                            <td class="Rrule" align="center">0.96 (0.56, 1.67)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">  <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">Stroke</span> (fatal and non-fatal)</td>
                            <td class="Rrule" align="center">155</td>
                            <td class="Rrule" align="center">(3.1)</td>
                            <td class="Rrule" align="center">117</td>
                            <td class="Rrule" align="center">(2.3)</td>
                            <td class="Rrule" align="center">0.75 (0.59, 0.96)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left"><span class="Bold">SECONDARY ENDPOINTS<a name="footnote-reference-11" href="#footnote-11" class="Sup">†</a></span></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">First <span class="conditions" mdrptid="35205243" mdrpt="cardiac failure congestive">CHF</span> with hospitalization</td>
                            <td class="Rrule" align="center">164</td>
                            <td class="Rrule" align="center">(3.3)</td>
                            <td class="Rrule" align="center">122</td>
                            <td class="Rrule" align="center">(2.4)</td>
                            <td class="Rrule" align="center">0.74 (0.59, 0.94)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">First PVD endpoint</td>
                            <td class="Rrule" align="center">282</td>
                            <td class="Rrule" align="center">(5.6)</td>
                            <td class="Rrule" align="center">275</td>
                            <td class="Rrule" align="center">(5.5)</td>
                            <td class="Rrule" align="center">0.97 (0.83, 1.15)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">
                                First <span class="conditions" mdrptid="37522318" mdrpt="coronary artery bypass">CABG</span> or other <span class="conditions" mdrptid="37522320" mdrpt="coronary revascularisation">coronary revascularization</span> procedure<a name="footnote-reference-12" href="#footnote-12" class="Sup">‡</a>
                            </td>
                            <td class="Rrule" align="center">904</td>
                            <td class="Rrule" align="center">(18.1)</td>
                            <td class="Rrule" align="center">667</td>
                            <td class="Rrule" align="center">(13.4)</td>
                            <td class="Rrule" align="center">0.72 (0.65, 0.80)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">
                                First documented <span class="conditions" mdrptid="35205181" mdrpt="angina pectoris">angina</span> endpoint<a href="#footnote-12" class="Sup">‡</a>
                            </td>
                            <td class="Rrule" align="center">615</td>
                            <td class="Rrule" align="center">(12.3)</td>
                            <td class="Rrule" align="center">545</td>
                            <td class="Rrule" align="center">(10.9)</td>
                            <td class="Rrule" align="center">0.88 (0.79, 0.99)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">All-cause mortality </td>
                            <td class="Rrule" align="center">282</td>
                            <td class="Rrule" align="center">(5.6)</td>
                            <td class="Rrule" align="center">284</td>
                            <td class="Rrule" align="center">(5.7)</td>
                            <td class="Rrule" align="center">1.01 (0.85, 1.19)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left"><span class="Bold">Components of All-Cause Mortality</span></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                            <td class="Rrule" align="center"></td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">  Cardiovascular <span class="conditions" mdrptid="35809059" mdrpt="death">death</span></td>
                            <td class="Rrule" align="center">155</td>
                            <td class="Rrule" align="center">(3.1)</td>
                            <td class="Rrule" align="center">126</td>
                            <td class="Rrule" align="center">(2.5)</td>
                            <td class="Rrule" align="center">0.81 (0.64, 1.03)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">  Noncardiovascular <span class="conditions" mdrptid="35809059" mdrpt="death">death</span></td>
                            <td class="Rrule" align="center">127</td>
                            <td class="Rrule" align="center">(2.5)</td>
                            <td class="Rrule" align="center">158</td>
                            <td class="Rrule" align="center">(3.2)</td>
                            <td class="Rrule" align="center">1.25 (0.99, 1.57)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">    <span class="conditions" mdrptid="36617300" mdrpt="neoplasm malignant">Cancer</span> <span class="conditions" mdrptid="35809059" mdrpt="death">death</span></td>
                            <td class="Rrule" align="center">75</td>
                            <td class="Rrule" align="center">(1.5)</td>
                            <td class="Rrule" align="center">85</td>
                            <td class="Rrule" align="center">(1.7)</td>
                            <td class="Rrule" align="center">1.13 (0.83, 1.55)</td>
                        </tr>
                        <tr class="Botrule">
                            <td class="Lrule Rrule" align="left">    Other non-CV <span class="conditions" mdrptid="35809059" mdrpt="death">death</span></td>
                            <td class="Rrule" align="center">43</td>
                            <td class="Rrule" align="center">(0.9)</td>
                            <td class="Rrule" align="center">58</td>
                            <td class="Rrule" align="center">(1.2)</td>
                            <td class="Rrule" align="center">1.35 (0.91, 2.00)</td>
                        </tr>
                        <tr class="Last">
                            <td class="Lrule Rrule" align="left">    <span class="conditions" mdrptid="36919230" mdrpt="completed suicide">Suicide</span>, <span class="conditions" mdrptid="37420481" mdrpt="homicide">homicide</span>, and other traumatic non-CV <span class="conditions" mdrptid="35809059" mdrpt="death">death</span></td>
                            <td class="Rrule" align="center">9</td>
                            <td class="Rrule" align="center">(0.2)</td>
                            <td class="Rrule" align="center">15</td>
                            <td class="Rrule" align="center">(0.3)</td>
                            <td class="Rrule" align="center">1.67 (0.73, 3.82)</td>
                        </tr>
                    </tbody>
                </table>
                <p>Of the events that comprised the primary efficacy endpoint, treatment with LIPITOR 80 mg/day significantly reduced the rate of non-fatal, non-procedure related MI and fatal and non-fatal <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span>, but not CHD <span class="conditions" mdrptid="35809059" mdrpt="death">death</span> or resuscitated <span class="conditions" mdrptid="35204966" mdrpt="cardiac arrest">cardiac arrest</span> (Table 5). Of the predefined secondary endpoints, treatment with LIPITOR 80 mg/day significantly reduced the rate of <span class="conditions" mdrptid="37522320" mdrpt="coronary revascularisation">coronary revascularization</span>, <span class="conditions" mdrptid="35205181" mdrpt="angina pectoris">angina</span>, and hospitalization for <span class="conditions" mdrptid="35205240" mdrpt="cardiac failure">heart failure</span>, but not <span class="conditions" mdrptid="37622501" mdrpt="peripheral vascular disorder">peripheral vascular disease</span>. The reduction in the rate of <span class="conditions" mdrptid="35205243" mdrpt="cardiac failure congestive">CHF</span> with hospitalization was only observed in the 8% of patients with a prior history of <span class="conditions" mdrptid="35205243" mdrpt="cardiac failure congestive">CHF</span>. </p>
                <p>There was no significant difference between the treatment groups for all-cause mortality (Table 5). The proportions of subjects who experienced cardiovascular <span class="conditions" mdrptid="35809059" mdrpt="death">death</span>, including the components of CHD <span class="conditions" mdrptid="35809059" mdrpt="death">death</span> and fatal <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span>, were numerically smaller in the LIPITOR 80 mg group than in the LIPITOR 10 mg treatment group. The proportions of subjects who experienced noncardiovascular <span class="conditions" mdrptid="35809059" mdrpt="death">death</span> were numerically larger in the LIPITOR 80 mg group than in the LIPITOR 10 mg treatment group.</p>
                <p>In the Incremental Decrease in Endpoints Through Aggressive Lipid Lowering Study (IDEAL), treatment with LIPITOR 80 mg/day was compared to treatment with simvastatin 20–40 mg/day in 8,888 subjects up to 80 years of age with a history of CHD to assess whether reduction in CV risk could be achieved. Patients were mainly male (81%), white (99%) with an average age of 61.7 years, and an average <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C of 121.5 mg/dL at randomization; 76% were on statin therapy. In this prospective, randomized, open-label, blinded endpoint (PROBE) trial with no run-in period, subjects were followed for a median duration of 4.8 years. The mean <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, TC, TG, HDL, and non-HDL <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> levels at Week 12 were 78, 145, 115, 45, and 100 mg/dL during treatment with 80 mg of LIPITOR and 105, 179, 142, 47, and 132 mg/dL during treatment with 20–40 mg of simvastatin. </p>
                <p>There was no significant difference between the treatment groups for the primary endpoint, the rate of first major coronary event (fatal CHD, non-fatal MI, and resuscitated <span class="conditions" mdrptid="35204966" mdrpt="cardiac arrest">cardiac arrest</span>): 411 (9.3%) in the LIPITOR 80 mg/day group vs. 463 (10.4%) in the simvastatin 20–40 mg/day group, HR 0.89, 95% CI ( 0.78, 1.01), p=0.07. </p>
                <p>There were no significant differences between the treatment groups for all-cause mortality: 366 (8.2%) in the LIPITOR 80 mg/day group vs. 374 (8.4%) in the simvastatin 20–40 mg/day group. The proportions of subjects who experienced CV or non-CV <span class="conditions" mdrptid="35809059" mdrpt="death">death</span> were similar for the LIPITOR 80 mg group and the simvastatin 20–40 mg group. </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S14.2"></a><a name="section-13.2"></a><p></p>
                <h2>14.2  <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">Hyperlipidemia</span> (Heterozygous Familial and Nonfamilial) and Mixed <span class="conditions" mdrptid="36416641" mdrpt="dyslipidaemia">Dyslipidemia</span> <span class="Italics">(Fredrickson</span> Types IIa and IIb)</h2>
                <p class="First">LIPITOR reduces total-C, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, VLDL-C, apo B, and TG, and increases HDL-C in patients with <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">hyperlipidemia</span> and mixed <span class="conditions" mdrptid="36416641" mdrpt="dyslipidaemia">dyslipidemia</span>. Therapeutic response is seen within 2 weeks, and maximum response is usually achieved within 4 weeks and maintained during chronic therapy.</p>
                <p>LIPITOR is effective in a wide variety of patient populations with <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">hyperlipidemia</span>, with and without <span class="conditions" mdrptid="36416637" mdrpt="hypertriglyceridaemia">hypertriglyceridemia</span>, in men and women, and in the <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span>. </p>
                <p>In two multicenter, placebo-controlled, dose-response studies in patients with <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">hyperlipidemia</span>, LIPITOR given as a single dose over 6 weeks, significantly reduced total-C, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, apo B, and TG. (Pooled results are provided in <a href="#table6">Table 6</a>.)</p>
                <a name="table6"></a><table width="80%">
                    <caption><span>TABLE 6. Dose Response in Patients With Primary <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">Hyperlipidemia</span> (Adjusted Mean % Change From Baseline)<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a></span></caption>
                    <col align="center" valign="top" width="16%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <thead>
                        <tr class="First Last">
                            <th align="center">Dose</th>
                            <th align="center">N</th>
                            <th align="center">TC</th>
                            <th align="center"><span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C</th>
                            <th align="center">Apo B</th>
                            <th align="center">TG</th>
                            <th align="center">HDL-C</th>
                            <th align="center">Non-HDL-C/ HDL-C</th>
                        </tr>
                    </thead>
                    <tfoot>
                        <tr>
                            <td colspan="8" align="left">
                                <dl class="Footnote">
                                    <dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
                                    <dd>Results are pooled from 2 dose-response studies.</dd>
                                </dl>
                            </td>
                        </tr>
                    </tfoot>
                    <tbody>
                        <tr class="First">
                            <td align="center">Placebo</td>
                            <td align="center">21</td>
                            <td align="center">4</td>
                            <td align="center">4</td>
                            <td align="center">3</td>
                            <td align="center">10</td>
                            <td align="center">-3</td>
                            <td align="center">7</td>
                        </tr>
                        <tr>
                            <td align="center">10</td>
                            <td align="center">22</td>
                            <td align="center">-29</td>
                            <td align="center">-39</td>
                            <td align="center">-32</td>
                            <td align="center">-19</td>
                            <td align="center">6</td>
                            <td align="center">-34</td>
                        </tr>
                        <tr>
                            <td align="center">20</td>
                            <td align="center">20</td>
                            <td align="center">-33</td>
                            <td align="center">-43</td>
                            <td align="center">-35</td>
                            <td align="center">-26</td>
                            <td align="center">9</td>
                            <td align="center">-41</td>
                        </tr>
                        <tr>
                            <td align="center">40</td>
                            <td align="center">21</td>
                            <td align="center">-37</td>
                            <td align="center">-50</td>
                            <td align="center">-42</td>
                            <td align="center">-29</td>
                            <td align="center">6</td>
                            <td align="center">-45</td>
                        </tr>
                        <tr class="Last">
                            <td align="center">80</td>
                            <td align="center">23</td>
                            <td align="center">-45</td>
                            <td align="center">-60</td>
                            <td align="center">-50</td>
                            <td align="center">-37</td>
                            <td align="center">5</td>
                            <td align="center">-53</td>
                        </tr>
                    </tbody>
                </table>
                <p>In patients with <span class="Italics">Fredrickson </span>Types IIa and IIb <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">hyperlipoproteinemia</span> pooled from 24 controlled trials, the median (25<span class="Sup">th</span> and 75<span class="Sup">th</span> percentile) percent changes from baseline in HDL-C for LIPITOR 10, 20, 40, and 80 mg were 6.4 (-1.4, 14), 8.7 (0, 17), 7.8 (0, 16), and 5.1 (-2.7, 15), respectively. Additionally, analysis of the pooled data demonstrated consistent and significant decreases in total-C, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, TG, total-C/HDL-C, and <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C/HDL-C.</p>
                <p>In three multicenter, double-blind studies in patients with <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">hyperlipidemia</span>, LIPITOR was compared to other statins. After randomization, patients were treated for 16 weeks with either LIPITOR 10 mg per day or a fixed dose of the comparative agent (<a href="#table7">Table 7</a>).</p>
                <a name="table7"></a><table width="100%">
                    <caption><span>TABLE 7. Mean Percentage Change From Baseline at Endpoint (Double-Blind, Randomized, Active-Controlled Trials)</span></caption>
                    <col align="left" valign="top" width="16%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <col align="center" valign="top" width="12%">
                    <thead>
                        <tr class="First Last">
                            <th align="center">Treatment<br>(Daily Dose)</th>
                            <th align="center" valign="bottom">N</th>
                            <th align="center" valign="bottom">Total-C</th>
                            <th align="center" valign="bottom"><span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C</th>
                            <th align="center" valign="bottom">Apo B</th>
                            <th align="center" valign="bottom">TG</th>
                            <th align="center" valign="bottom">HDL-C</th>
                            <th align="center" valign="bottom">Non-HDL-C/ HDL-C</th>
                        </tr>
                    </thead>
                    <tfoot>
                        <tr>
                            <td colspan="8" align="left">
                                <dl class="Footnote">
                                    <dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
                                    <dd>Significantly different from lovastatin, ANCOVA, p ≤0.05</dd>
                                    <dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
                                    <dd>A negative value for the 95% CI for the difference between treatments favors LIPITOR for all except HDL-C, for which a positive value favors LIPITOR. If the range does not include 0, this indicates a statistically significant difference.</dd>
                                    <dt><a name="footnote-16" href="#footnote-reference-16">‡</a></dt>
                                    <dd>Significantly different from pravastatin, ANCOVA, p ≤0.05</dd>
                                    <dt><a name="footnote-17" href="#footnote-reference-17">§</a></dt>
                                    <dd>Significantly different from simvastatin, ANCOVA, p ≤0.05</dd>
                                </dl>
                            </td>
                        </tr>
                    </tfoot>
                    <tbody>
                        <tr class="First">
                            <td align="left"><span class="Italics">Study 1</span></td>
                            <td align="center"></td>
                            <td align="center"></td>
                            <td align="center"></td>
                            <td align="center"></td>
                            <td align="center"></td>
                            <td align="center"></td>
                            <td align="center"></td>
                        </tr>
                        <tr>
                            <td align="left">LIPITOR 10 mg</td>
                            <td align="center">707</td>
                            <td align="center">
                                -27<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a>
                            </td>
                            <td align="center">
                                -36<a href="#footnote-14" class="Sup">*</a>
                            </td>
                            <td align="center">
                                -28<a href="#footnote-14" class="Sup">*</a>
                            </td>
                            <td align="center">
                                -17<a href="#footnote-14" class="Sup">*</a>
                            </td>
                            <td align="center">+7</td>
                            <td align="center">
                                -37<a href="#footnote-14" class="Sup">*</a>
                            </td>
                        </tr>
                        <tr>
                            <td align="left">Lovastatin 20 mg</td>
                            <td align="center">191</td>
                            <td align="center">-19</td>
                            <td align="center">-27</td>
                            <td align="center">-20</td>
                            <td align="center">-6</td>
                            <td align="center">+7</td>
                            <td align="center">-28</td>
                        </tr>
                        <tr>
                            <td align="left">
                                95% CI for Diff<a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a>
                            </td>
                            <td align="center"></td>
                            <td align="center">-9.2, -6.5</td>
                            <td align="center">-10.7, -7.1</td>
                            <td align="center">-10.0, -6.5</td>
                            <td align="center">-15.2, -7.1</td>
                            <td align="center">-1.7, 2.0</td>
                            <td align="center">-11.1, -7.1</td>
                        </tr>
                        <tr>
                            <td class="Toprule" align="left"><span class="Italics">Study 2</span></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                        </tr>
                        <tr>
                            <td align="left">LIPITOR 10 mg</td>
                            <td align="center">222</td>
                            <td align="center">
                                -25<a name="footnote-reference-16" href="#footnote-16" class="Sup">‡</a>
                            </td>
                            <td align="center">
                                -35<a href="#footnote-16" class="Sup">‡</a>
                            </td>
                            <td align="center">
                                -27<a href="#footnote-16" class="Sup">‡</a>
                            </td>
                            <td align="center">
                                -17<a href="#footnote-16" class="Sup">‡</a>
                            </td>
                            <td align="center">+6</td>
                            <td align="center">
                                -36<a href="#footnote-16" class="Sup">‡</a>
                            </td>
                        </tr>
                        <tr>
                            <td align="left">Pravastatin 20 mg</td>
                            <td align="center">77</td>
                            <td align="center">-17</td>
                            <td align="center">-23</td>
                            <td align="center">-17</td>
                            <td align="center">-9</td>
                            <td align="center">+8</td>
                            <td align="center">-28</td>
                        </tr>
                        <tr>
                            <td align="left">
                                95% CI for Diff<a href="#footnote-15" class="Sup">†</a>
                            </td>
                            <td align="center"></td>
                            <td align="center">-10.8, -6.1</td>
                            <td align="center">-14.5, -8.2</td>
                            <td align="center">-13.4, -7.4</td>
                            <td align="center">-14.1, -0.7</td>
                            <td align="center">-4.9, 1.6</td>
                            <td align="center">-11.5, -4.1</td>
                        </tr>
                        <tr>
                            <td class="Toprule" align="left"><span class="Italics">Study 3</span></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                            <td class="Toprule" align="center"></td>
                        </tr>
                        <tr>
                            <td align="left">LIPITOR 10 mg</td>
                            <td align="center">132</td>
                            <td align="center">
                                -29<a name="footnote-reference-17" href="#footnote-17" class="Sup">§</a>
                            </td>
                            <td align="center">
                                -37<a href="#footnote-17" class="Sup">§</a>
                            </td>
                            <td align="center">
                                -34<a href="#footnote-17" class="Sup">§</a>
                            </td>
                            <td align="center">
                                -23<a href="#footnote-17" class="Sup">§</a>
                            </td>
                            <td align="center">+7</td>
                            <td align="center">
                                -39<a href="#footnote-17" class="Sup">§</a>
                            </td>
                        </tr>
                        <tr>
                            <td align="left">Simvastatin 10 mg</td>
                            <td align="center">45</td>
                            <td align="center">-24</td>
                            <td align="center">-30</td>
                            <td align="center">-30</td>
                            <td align="center">-15</td>
                            <td align="center">+7</td>
                            <td align="center">-33</td>
                        </tr>
                        <tr class="Last">
                            <td align="left">
                                95% CI for Diff<a href="#footnote-15" class="Sup">†</a>
                            </td>
                            <td align="center"></td>
                            <td align="center">-8.7, -2.7</td>
                            <td align="center">-10.1, -2.6</td>
                            <td align="center">-8.0, -1.1</td>
                            <td align="center">-15.1, -0.7</td>
                            <td align="center">-4.3, 3.9</td>
                            <td align="center">-9.6, -1.9</td>
                        </tr>
                    </tbody>
                </table>
                <p>The impact on clinical outcomes of the differences in lipid-altering effects between treatments shown in Table 7 is not known. Table 7 does not contain data comparing the effects of LIPITOR 10 mg and higher doses of lovastatin, pravastatin, and simvastatin. The drugs compared in the studies summarized in the table are not necessarily interchangeable.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S14.3"></a><a name="section-13.3"></a><p></p>
                <h2>14.3  <span class="conditions" mdrptid="36416637" mdrpt="hypertriglyceridaemia">Hypertriglyceridemia</span> <span class="Italics">(Fredrickson</span> Type IV)</h2>
                <p class="First">The response to LIPITOR in 64 patients with isolated <span class="conditions" mdrptid="36416637" mdrpt="hypertriglyceridaemia">hypertriglyceridemia</span> treated across several clinical trials is shown in the table below (<a href="#table8">Table 8</a>). For the LIPITOR-treated patients, median (min, max) baseline TG level was 565 (267–1502).</p>
                <a name="table8"></a><table width="100%">
                    <caption><span>TABLE 8. Combined Patients With Isolated Elevated TG: Median (min, max) Percentage Change From Baseline</span></caption>
                    <col align="left" valign="middle" width="20%">
                    <col align="center" valign="middle" width="20%">
                    <col align="center" valign="middle" width="20%">
                    <col align="center" valign="middle" width="20%">
                    <col align="center" valign="middle" width="20%">
                    <thead>
                        <tr class="First Last">
                            <th align="left"></th>
                            <th align="center">Placebo<br> (N=12)</th>
                            <th align="center">LIPITOR 10 mg<br> (N=37)</th>
                            <th align="center">LIPITOR 20 mg<br> (N=13)</th>
                            <th align="center">LIPITOR 80 mg<br> (N=14)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="Botrule First">
                            <td align="left"><span class="conditions" mdrptid="36314070" mdrpt="blood triglycerides">Triglycerides</span></td>
                            <td align="center">-12.4 (-36.6, 82.7)</td>
                            <td align="center">-41.0 (-76.2, 49.4)</td>
                            <td align="center">-38.7 (-62.7, 29.5)</td>
                            <td align="center">-51.8 (-82.8, 41.3)</td>
                        </tr>
                        <tr class="Botrule">
                            <td align="left">Total-C</td>
                            <td align="center">-2.3 (-15.5, 24.4)</td>
                            <td align="center">-28.2 (-44.9, -6.8)</td>
                            <td align="center">-34.9 (-49.6, -15.2)</td>
                            <td align="center">-44.4 (-63.5, -3.8)</td>
                        </tr>
                        <tr class="Botrule">
                            <td align="left"><span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C</td>
                            <td align="center">3.6 (-31.3, 31.6)</td>
                            <td align="center">-26.5 (-57.7, 9.8)</td>
                            <td align="center">-30.4 (-53.9, 0.3)</td>
                            <td align="center">-40.5 (-60.6, -13.8)</td>
                        </tr>
                        <tr class="Botrule">
                            <td align="left">HDL-C</td>
                            <td align="center">3.8 (-18.6, 13.4)</td>
                            <td align="center">13.8 (-9.7, 61.5)</td>
                            <td align="center">11.0 (-3.2, 25.2)</td>
                            <td align="center">7.5 (-10.8, 37.2)</td>
                        </tr>
                        <tr class="Botrule">
                            <td align="left">VLDL-C</td>
                            <td align="center">-1.0 (-31.9, 53.2)</td>
                            <td align="center">-48.8 (-85.8, 57.3)</td>
                            <td align="center">-44.6 (-62.2, -10.8)</td>
                            <td align="center">-62.0 (-88.2, 37.6)</td>
                        </tr>
                        <tr class="Last">
                            <td align="left">non-HDL-C</td>
                            <td align="center">-2.8 (-17.6, 30.0)</td>
                            <td align="center">-33.0 (-52.1, -13.3)</td>
                            <td align="center">-42.7 (-53.7, -17.4)</td>
                            <td align="center">-51.5 (-72.9, -4.3)</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S14.4"></a><a name="section-13.4"></a><p></p>
                <h2>14.4  Dysbetalipoproteinemia <span class="Italics">(Fredrickson</span> Type III)</h2>
                <p class="First">The results of an open-label crossover study of 16 patients (genotypes: 14 apo E2/E2 and 2 apo E3/E2) with dysbetalipoproteinemia <span class="Italics">(Fredrickson </span>Type III) are shown in the table below (<a href="#table9">Table 9</a>).</p>
                <a name="table9"></a><table width="100%">
                    <caption><span>TABLE 9. Open-Label Crossover Study of 16 Patients With Dysbetalipoproteinemia (Fredrickson Type III)</span></caption>
                    <col align="left" valign="bottom" width="25%">
                    <col align="center" valign="bottom" width="25%">
                    <col align="center" valign="bottom" width="25%">
                    <col align="center" valign="bottom" width="25%">
                    <thead>
                        <tr class="First">
                            <th align="left"></th>
                            <th align="center"></th>
                            <th class="Botrule" align="center" colspan="2">Median % Change (min, max)</th>
                        </tr>
                        <tr class="Last">
                            <th align="left"></th>
                            <th align="center">Median (min, max) at Baseline (mg/dL)</th>
                            <th align="center">LIPITOR 10 mg</th>
                            <th align="center">LIPITOR 80 mg</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="Botrule First">
                            <td align="left">Total-C</td>
                            <td align="center">442 (225, 1320)</td>
                            <td align="center">-37 (-85, 17)</td>
                            <td align="center">-58 (-90, -31)</td>
                        </tr>
                        <tr class="Botrule">
                            <td align="left"><span class="conditions" mdrptid="36314070" mdrpt="blood triglycerides">Triglycerides</span></td>
                            <td align="center">678 (273, 5990)</td>
                            <td align="center">-39 (-92, -8)</td>
                            <td align="center">-53 (-95, -30)</td>
                        </tr>
                        <tr class="Botrule">
                            <td align="left">IDL-C + VLDL-C</td>
                            <td align="center">215 (111, 613)</td>
                            <td align="center">-32 (-76, 9)</td>
                            <td align="center">-63 (-90, -8)</td>
                        </tr>
                        <tr class="Last">
                            <td align="left">non-HDL-C</td>
                            <td align="center">411 (218, 1272)</td>
                            <td align="center">-43 (-87, -19)</td>
                            <td align="center">-64 (-92, -36)</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S14.5"></a><a name="section-13.5"></a><p></p>
                <h2>14.5  <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">Homozygous Familial Hypercholesterolemia</span></h2>
                <p class="First">In a study without a concurrent control group, 29 patients ages 6 to 37 years with homozygous FH received maximum daily doses of 20 to 80 mg of LIPITOR. The mean <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C reduction in this study was 18%. Twenty-five patients with a reduction in <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C had a mean response of 20% (range of 7% to 53%, median of 24%); the remaining 4 patients had 7% to 24% increases in <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C. Five of the 29 patients had absent <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-receptor function. Of these, 2 patients also had a <span class="conditions" mdrptid="37521360" mdrpt="portal shunt">portacaval shunt</span> and had no significant reduction in <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C. The remaining 3 receptor-negative patients had a mean <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C reduction of 22%.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S14.6"></a><a name="section-13.6"></a><p></p>
                <h2>14.6  <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">Heterozygous Familial Hypercholesterolemia</span> in Pediatric Patients</h2>
                <p class="First">In a double-blind, placebo-controlled study followed by an open-label phase, 187 boys and postmenarchal girls 10–17 years of age (mean age 14.1 years) with <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">heterozygous familial hypercholesterolemia</span> (FH) or severe <span class="conditions" mdrptid="36416634" mdrpt="hypercholesterolaemia">hypercholesterolemia</span>, were randomized to LIPITOR (n=140) or placebo (n=47) for 26 weeks and then all received LIPITOR for 26 weeks. Inclusion in the study required 1) a baseline <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C level ≥ 190 mg/dL or 2) a baseline <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C level ≥ 160 mg/dL and positive family history of FH or documented premature cardiovascular disease in a first or second-degree relative. The mean baseline <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C value was 218.6 mg/dL (range: 138.5–385.0 mg/dL) in the LIPITOR group compared to 230.0 mg/dL (range: 160.0–324.5 mg/dL) in the placebo group. The dosage of LIPITOR (once daily) was 10 mg for the first 4 weeks and uptitrated to 20 mg if the <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C level was &gt; 130 mg/dL. The number of LIPITOR-treated patients who required uptitration to 20 mg after Week 4 during the double-blind phase was 78 (55.7%).</p>
                <p>LIPITOR significantly decreased plasma levels of total-C, <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C, <span class="conditions" mdrptid="36314070" mdrpt="blood triglycerides">triglycerides</span>, and apolipoprotein B during the 26-week double-blind phase (see <a href="#table10">Table 10</a>).</p>
                <a name="table10"></a><table width="90%">
                    <caption><span>TABLE 10. Lipid-altering Effects of LIPITOR in Adolescent Boys and Girls with <span class="conditions" mdrptid="35305820" mdrpt="type iia hyperlipidaemia">Heterozygous Familial Hypercholesterolemia</span> or Severe <span class="conditions" mdrptid="36416634" mdrpt="hypercholesterolaemia">Hypercholesterolemia</span> (Mean Percentage Change From Baseline at Endpoint in Intention-to-Treat Population)</span></caption>
                    <col align="left" valign="middle" width="14%">
                    <col align="center" valign="middle" width="10%">
                    <col align="center" valign="middle" width="14%">
                    <col align="center" valign="middle" width="14%">
                    <col align="center" valign="middle" width="14%">
                    <col align="center" valign="middle" width="14%">
                    <col align="center" valign="middle" width="20%">
                    <thead>
                        <tr class="First Last">
                            <th align="left">DOSAGE</th>
                            <th align="center">N</th>
                            <th align="center">Total-C</th>
                            <th align="center"><span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C</th>
                            <th align="center">HDL-C</th>
                            <th align="center">TG</th>
                            <th align="center">Apolipoprotein B</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="First">
                            <td align="left">Placebo</td>
                            <td align="center">47</td>
                            <td align="center">-1.5</td>
                            <td align="center">-0.4</td>
                            <td align="center">-1.9</td>
                            <td align="center">1.0</td>
                            <td align="center">0.7</td>
                        </tr>
                        <tr class="Last">
                            <td align="left">LIPITOR</td>
                            <td align="center">140</td>
                            <td align="center">-31.4</td>
                            <td align="center">-39.6</td>
                            <td align="center">2.8</td>
                            <td align="center">-12.0</td>
                            <td align="center">-34.0</td>
                        </tr>
                    </tbody>
                </table>
                <p>The mean achieved <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C value was 130.7 mg/dL (range: 70.0–242.0 mg/dL) in the LIPITOR group compared to 228.5 mg/dL (range: 152.0–385.0 mg/dL) in the placebo group during the 26-week double-blind phase.</p>
                <p>The safety and efficacy of doses above 20 mg have not been studied in controlled trials in children. The long-term efficacy of LIPITOR therapy in childhood to reduce morbidity and mortality in adulthood has not been established.</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34093-5">
            <a name="S15"></a><a name="section-14"></a><p></p>
            <h1>15  REFERENCES</h1>
            <dl>
                <dt>[1]</dt>
                <dd>National <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">Cholesterol</span> Education Program (NCEP): Highlights of the Report of the Expert Panel on <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">Blood Cholesterol</span> Levels in Children and Adolescents, <span class="Italics">Pediatrics.</span> 89(3):495–501. 1992.</dd>
            </dl>
        </div>
        <div class="Section" data-sectionCode="34069-5">
            <a name="S16"></a><a name="section-15"></a><p></p>
            <h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
            <p class="First"><span class="Bold">10 mg tablets: </span>coded "PD 155" on one side and "10" on the other.</p>
            <p>NDC 0071-0155-23 bottles of 90<br>NDC 0071-0155-34 bottles of 5000<br>NDC 0071-0155-40 10 × 10 unit dose <span class="conditions" mdrptid="36211383" mdrpt="blister">blisters</span><br>NDC 0071-0155-10 bottles of 1000</p>
            <p><span class="Bold">20 mg tablets: </span>coded "PD 156" on one side and "20" on the other.</p>
            <p>NDC 0071-0156-23 bottles of 90<br>NDC 0071-0156-40 10 × 10 unit dose <span class="conditions" mdrptid="36211383" mdrpt="blister">blisters</span><br>NDC 0071-0156-94 bottles of 5000<br>NDC 0071-0156-10 bottles of 1000</p>
            <p><span class="Bold">40 mg tablets: </span>coded "PD 157" on one side and "40" on the other.</p>
            <p>NDC 0071-0157-23 bottles of 90<br>NDC 0071-0157-73 bottles of 500<br>NDC 0071-0157-88 bottles of 2500<br>NDC 0071-0157-40 10 × 10 unit dose <span class="conditions" mdrptid="36211383" mdrpt="blister">blisters</span></p>
            <p><span class="Bold">80 mg tablets:</span> coded "PD 158" on one side and "80" on the other.</p>
            <p>NDC 0071-0158-23 bottles of 90<br>NDC 0071-0158-73 bottles of 500<br>NDC 0071-0158-88 bottles of 2500<br>NDC 0071-0158-92 8 × 8 unit dose <span class="conditions" mdrptid="36211383" mdrpt="blister">blisters</span></p>
            <div class="Section" data-sectionCode="44425-7">
                <a name="section-15.1"></a><p></p>
                <p class="First"><span class="Bold">Storage</span></p>
                <p>Store at controlled room temperature 20 – 25°C (68 – 77°F) [see USP].</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34076-0">
            <a name="S17"></a><a name="section-16"></a><p></p>
            <h1>17  PATIENT COUNSELING INFORMATION</h1>
            <p class="First">Patients taking LIPITOR should be advised that <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> is a chronic condition and they should adhere to their medication along with their National <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">Cholesterol</span> Education Program (NCEP)-recommended diet, a regular <span class="conditions" mdrptid="37420574" mdrpt="exercise adequate">exercise</span> program as appropriate, and periodic testing of a <span class="conditions" mdrptid="37420500" mdrpt="fasting">fasting</span> lipid panel to determine goal attainment. </p>
            <p><span class="Bold">Patients should be advised about substances they should not take concomitantly with atorvastatin <span class="Italics">[</span>see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>. Patients should also be advised to inform other healthcare professionals prescribing a new medication that they are taking LIPITOR.</span></p>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S17.1"></a><a name="section-16.1"></a><p></p>
                <h2>17.1	<span class="conditions" mdrptid="36516837" mdrpt="myalgia">Muscle Pain</span></h2>
                <p class="First">All patients starting therapy with LIPITOR should be advised of the risk of <span class="conditions" mdrptid="36516886" mdrpt="myopathy">myopathy</span> and told to report promptly any unexplained <span class="conditions" mdrptid="36516837" mdrpt="myalgia">muscle pain</span>, <span class="conditions" mdrptid="35809252" mdrpt="tenderness">tenderness</span>, or <span class="conditions" mdrptid="35809072" mdrpt="asthenia">weakness</span>  particularly if accompanied by <span class="conditions" mdrptid="35809079" mdrpt="malaise">malaise</span> or <span class="conditions" mdrptid="35809054" mdrpt="pyrexia">fever</span> or if these muscle signs or symptoms persist after discontinuing LIPITOR. The risk of this occurring is increased when taking certain types of medication or consuming larger quantities (&gt;1 liter) of grapefruit juice. They should discuss all medication, both prescription and over the counter, with their healthcare professional.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S17.2"></a><a name="section-16.2"></a><p></p>
                <h2>17.2 Liver Enzymes</h2>
                <p class="First">It is recommended that liver enzyme tests be performed before the initiation of LIPITOR and if signs or symptoms of <span class="conditions" mdrptid="35909503" mdrpt="liver injury">liver injury</span> occur. All patients treated with LIPITOR should be advised to report promptly any symptoms that may indicate <span class="conditions" mdrptid="35909503" mdrpt="liver injury">liver injury</span>, including <span class="conditions" mdrptid="35809076" mdrpt="fatigue">fatigue</span>, anorexia, right <span class="conditions" mdrptid="35708164" mdrpt="abdominal discomfort">upper abdominal discomfort</span>, dark urine, or <span class="conditions" mdrptid="35104306" mdrpt="jaundice">jaundice</span>.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S17.3"></a><a name="section-16.3"></a><p></p>
                <h2>17.3	<span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span></h2>
                <p class="First">Women of childbearing age should be advised to use an effective method of <span class="conditions" mdrptid="37521562" mdrpt="contraception">birth control</span> to prevent <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> while using LIPITOR. Discuss future <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> plans with your patients, and discuss when to stop LIPITOR if they are trying to conceive. Patients should be advised that if they become <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span>, they should stop taking LIPITOR and call their healthcare professional.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="S17.4"></a><a name="section-16.4"></a><p></p>
                <h2>17.4 Breast-feeding</h2>
                <p class="First">Women who are breastfeeding should be advised to not use LIPITOR. Patients who have a lipid disorder and are breast-feeding, should be advised to discuss the options with their healthcare professional.</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="42229-5">
            <a name="section-17"></a><p></p>
            <p class="First"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-05.jpg"></p>
            <p>LAB-0021-30.0</p>
        </div>
        <div class="Section" data-sectionCode="42230-3">
            <a name="section-18"></a><p></p>
            <h1>PATIENT INFORMATION</h1>
            <p class="First"><span class="Italics"><span class="Bold">LIPITOR<span class="Sub">®</span></span><br>atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span><br>tablets</span><br></p>
            <p>(LIP-ih-tore)</p>
            <p>Read the Patient Information that comes with LIPITOR before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment.</p>
            <p>If you have any questions about LIPITOR, ask your doctor or pharmacist.</p>
            <p><span class="Bold">What is LIPITOR?</span></p>
            <p>LIPITOR is a prescription medicine that lowers <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> in your blood. It lowers the <span class="conditions" mdrptid="36314006" mdrpt="low density lipoprotein">LDL</span>-C ("bad" <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span>) and <span class="conditions" mdrptid="36314070" mdrpt="blood triglycerides">triglycerides</span> in your blood. It can raise your HDL-C ("good" <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span>) as well. LIPITOR is for adults and children over 10 whose <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> does not come down enough with <span class="conditions" mdrptid="37420574" mdrpt="exercise adequate">exercise</span> and a low-fat diet alone.</p>
            <p>LIPITOR can lower the risk for <span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">heart attack</span>, <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span>, certain types of heart <span class="conditions" mdrptid="37522270" mdrpt="surgery">surgery</span>, and <span class="conditions" mdrptid="35205185" mdrpt="chest pain">chest pain</span> in patients who have heart disease or risk factors for heart disease such as:</p>
            <ul><li>age, smoking, high <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span>, <span class="conditions" mdrptid="36313993" mdrpt="high density lipoprotein decreased">low HDL</span>-C, heart disease in the family.</li></ul>
            <p>LIPITOR can lower the risk for <span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">heart attack</span> or <span class="conditions" mdrptid="36718005" mdrpt="cerebrovascular accident">stroke</span> in patients with <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span> and risk factors such as:</p>
            <ul><li>eye problems, kidney problems, smoking, or high <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span>.</li></ul>
            <p>LIPITOR starts to work in about 2 weeks. </p>
            <p><span class="Bold">What is <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">Cholesterol</span>?</span></p>
            <p><span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">Cholesterol</span> and <span class="conditions" mdrptid="36314070" mdrpt="blood triglycerides">triglycerides</span> are fats that are made in your body. They are also found in foods. You need some <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> for good health, but too much is not good for you. <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">Cholesterol</span> and <span class="conditions" mdrptid="36314070" mdrpt="blood triglycerides">triglycerides</span> can clog your blood vessels. It is especially important to lower your <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> if you have heart disease, smoke, have <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span> or high <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span>, are older, or if heart disease starts early in your family.</p>
            <p><span class="Bold">Who Should Not Take LIPITOR?</span></p>
            <p>Do not take LIPITOR if you:</p>
            <ul>
                <li>are <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> or think you may be <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span>, or are planning to become <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span>. Lipitor may harm your unborn baby. If you get <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span>, stop taking LIPITOR and call your doctor right away.</li>
                <li>are <span class="conditions" mdrptid="37420447" mdrpt="breast feeding">breast feeding</span><span class="Bold">.</span> LIPITOR can pass into your breast milk and may harm your baby.</li>
                <li>have liver problems.</li>
                <li>are allergic to LIPITOR or any of its ingredients. The active ingredient is atorvastatin. See the end of this leaflet for a complete list of ingredients in LIPITOR.</li>
            </ul>
            <p>LIPITOR has not been studied in children under 10 years of age.</p>
            <p><span class="Bold">Before You Start LIPITOR</span></p>
            <p>Tell your doctor if you: </p>
            <ul>
                <li>have muscle aches or <span class="conditions" mdrptid="35809072" mdrpt="asthenia">weakness</span></li>
                <li>drink more than 2 glasses of alcohol daily</li>
                <li>have <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span></li>
                <li>have a thyroid problem</li>
                <li>have kidney problems</li>
            </ul>
            <p>Some medicines should not be taken with LIPITOR. Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects. Especially tell your doctor if you take medicines for:</p>
            <ul>
                <li>your immune system</li>
                <li><span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span></li>
                <li>infections</li>
                <li><span class="conditions" mdrptid="37521562" mdrpt="contraception">birth control</span></li>
                <li><span class="conditions" mdrptid="35205240" mdrpt="cardiac failure">heart failure</span></li>
                <li>HIV or <span class="conditions" mdrptid="36009925" mdrpt="acquired immunodeficiency syndrome">AIDS</span></li>
            </ul>
            <p>Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist.</p>
            <p><span class="Bold">How Should I Take LIPITOR?</span></p>
            <ul>
                <li>Take LIPITOR exactly as prescribed by your doctor. Do not change your dose or stop LIPITOR without talking to your doctor. Your doctor may do blood tests to check your <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> levels during your treatment with LIPITOR. Your dose of LIPITOR may be changed based on these <span class="conditions" mdrptid="36313956" mdrpt="blood test">blood test</span> results.</li>
                <li>Take LIPITOR each day at any time of day at about the same time each day. LIPITOR can be taken with or without food.<br>Don't break LIPITOR tablets before taking. </li>
                <li>Your doctor should start you on a low-fat diet before giving you LIPITOR. Stay on this low-fat diet when you take LIPITOR.</li>
                <li>If you miss a dose of LIPITOR, take it as soon as you remember. Do not take LIPITOR if it has been more than 12 hours since you missed your last dose. Wait and take the next dose at your regular time. Do not take 2 doses of LIPITOR at the same time.</li>
                <li>If you take too much LIPITOR or <span class="conditions" mdrptid="36211496" mdrpt="overdose">overdose</span>, call your doctor or Poison Control Center right away. Or go to the nearest emergency room.</li>
            </ul>
            <p><span class="Bold">What Should I Avoid While Taking LIPITOR?</span></p>
            <ul>
                <li>Talk to your doctor before you start any new medicines. This includes prescription and non-prescription medicines, vitamins, and herbal supplements. LIPITOR and certain other medicines can interact causing serious side effects.</li>
                <li>Do not get <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span>. If you get <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span>, stop taking LIPITOR right away and call your doctor.</li>
            </ul>
            <p><span class="Bold">What are the Possible Side Effects of LIPITOR?</span></p>
            <p><span class="Bold">LIPITOR can cause serious side effects. These side effects have happened only to a small number of people. Your doctor can monitor you  for them. These side effects usually go away if your dose is lowered or LIPITOR is stopped. These serious side effects include: </span></p>
            <ul>
                <li>
                    <span class="Bold">Muscle problems. </span>LIPITOR can cause serious muscle problems that can lead to kidney problems, including <span class="conditions" mdrptid="37019318" mdrpt="renal failure">kidney failure</span>. You have a higher chance for muscle problems if you are taking certain other medicines with LIPITOR.
                </li>
                <li>
                    <span class="Bold">Liver problems. </span>Your doctor should do blood tests to check your liver before you start taking LIPITOR and if you have symptoms of liver problems while you take LIPITOR. Call your doctor right away if you have the following symptoms of liver problems:<ul class="Disc">
                        <li>feel tired or weak </li>
                        <li>loss of appetite</li>
                        <li>upper belly <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span></li>
                        <li>dark amber colored urine</li>
                        <li>yellowing of your skin or the whites of your eyes</li>
                    </ul>
                </li>
            </ul>
            <p><span class="Bold">Call your doctor right away if you have:</span></p>
            <ul>
                <li>muscle problems like <span class="conditions" mdrptid="35809072" mdrpt="asthenia">weakness</span>, <span class="conditions" mdrptid="35809252" mdrpt="tenderness">tenderness</span>, or <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> that happen without a good reason, especially if you also have a <span class="conditions" mdrptid="35809054" mdrpt="pyrexia">fever</span> or feel more tired than usual. This may be an early sign of a rare muscle problem.</li>
                <li>muscle problems that do not go away even after your doctor has advised you to stop taking LIPITOR. Your doctor may do further tests to diagnose the cause of your muscle problems.</li>
                <li>allergic reactions including <span class="conditions" mdrptid="35809166" mdrpt="swelling">swelling</span> of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing which may require treatment right away.</li>
                <li><span class="conditions" mdrptid="35708208" mdrpt="vomiting">nausea and vomiting</span>.</li>
                <li>passing brown or dark-colored urine.</li>
                <li>you feel more tired than usual</li>
                <li>your skin and whites of your eyes get yellow.</li>
                <li><span class="conditions" mdrptid="35708156" mdrpt="abdominal pain upper">stomach pain</span>.</li>
                <li>allergic skin reactions.</li>
            </ul>
            <p>In clinical studies, patients reported the following common side effects while taking LIPITOR: <span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">diarrhea</span>, <span class="conditions" mdrptid="35708164" mdrpt="abdominal discomfort">upset stomach</span>, muscle and <span class="conditions" mdrptid="36516812" mdrpt="arthralgia">joint pain</span>, and alterations in some laboratory blood tests. </p>
            <p>The following additional side effects have been reported with LIPITOR:</p>
            <p><span class="conditions" mdrptid="35809076" mdrpt="fatigue">tiredness</span>, tendon problems, <span class="conditions" mdrptid="36718171" mdrpt="amnesia">memory loss</span>, and <span class="conditions" mdrptid="36718301" mdrpt="confusional state">confusion</span>. </p>
            <p>Talk to your doctor or pharmacist if you have side effects that bother you or that will not go away.</p>
            <p>These are not all the side effects of LIPITOR. Ask your doctor or pharmacist for a complete list.</p>
            <p><span class="Bold">How do I store LIPITOR</span></p>
            <ul>
                <li>Store LIPITOR at room temperature, 68 to 77°F (20 to 25°C).</li>
                <li>Do not keep medicine that is out of date or that you no longer need.</li>
                <li>
                    <span class="Bold">Keep LIPITOR and all medicines out of the reach of children. </span>Be sure that if you throw medicine away, it is out of the reach of children.
                </li>
            </ul>
            <p><span class="Bold">General Information About LIPITOR</span></p>
            <p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use LIPITOR for a condition for which it was not prescribed. Do not give LIPITOR to other people, even if they have the same problem you have. It may harm them.</p>
            <p>This leaflet summarizes the most important information about LIPITOR. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about LIPITOR that is written for health professionals. Or you can go to the LIPITOR website at www.lipitor.com. </p>
            <p><span class="Bold">What are the Ingredients in LIPITOR?</span></p>
            <p><span class="Bold">Active Ingredient:</span> atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span></p>
            <p><span class="Bold">Inactive Ingredients:  </span><span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> carbonate, USP; candelilla wax, FCC; croscarmellose <span class="conditions" mdrptid="36316389" mdrpt="blood sodium">sodium</span>, NF; hydroxypropyl cellulose, NF; lactose monohydrate, NF; magnesium stearate, NF; microcrystalline cellulose, NF; Opadry White YS-1-7040 (hypromellose, polyethylene glycol, talc, titanium dioxide); polysorbate 80, NF; simethicone emulsion.</p>
            <p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-05.jpg"></p>
            <p><span class="Bold">LAB-0348-8.0  <br>October 2012</span></p>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-19"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label</span></p>
            <p>NDC 0071-0155-23</p>
            <p><span class="Bold Italics">Pfizer</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span><br>(atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>)</p>
            <p><span class="Bold">10 mg*</span></p>
            <p><span class="Bold">tablets</span></p>
            <p>90 Tablets<br><span class="Bold">Rx only</span></p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-06.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-20"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mg Tablet <span class="conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span></p>
            <p>(Atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">Calcium</span>)<br>Tablet</p>
            <p><span class="Bold">10 mg</span></p>
            <p>DISTRIBUTED BY:<br>PARKE-DAVIS<br>DIV OF PFIZER INC, NY, NY 10017<br>MADE IN IRELAND</p>
            <p>EXP &amp; LOT AREA</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg Tablet <span class=" conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-07.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-21"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mg <span class="conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack Carton</span></p>
            <p><span class="Bold Italics">Pfizer</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span><br>(atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>)</p>
            <p><span class="Bold">10 mg*</span></p>
            <p><span class="Bold">tablets</span></p>
            <p>For in-institution use only</p>
            <p>100 Tablets</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg <span class=" conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-08.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-22"></a><p></p>
            <h1>PRINCIPAL DISPLAY PANEL - 10 mg Tablet Packet Carton</h1>
            <p class="First">NDC 0071-0155-97<br><span class="Bold">PROFESSIONAL SAMPLE – NOT FOR SALE</span></p>
            <p><span class="Bold Italics">LIPITOR</span><span class="Sub">®</span><br><span class="Italics">atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span><br><span class="Bold">tablets</span></span></p>
            <p><span class="Bold">10 mg*</span><br><span class="Bold Italics">7 TABLETS</span></p>
            <p>PACKAGE NOT CHILD RESISTANT.<br>KEEP OUT OF REACH OF CHILDREN.</p>
            <p><span class="Bold">Rx only</span></p>
            <p><span class="Bold Italics">Patient information enclosed</span></p>
            <p>7 Tablets x 10 mg</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg Tablet Packet Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-09.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-23"></a><p></p>
            <h1>PRINCIPAL DISPLAY PANEL - 10 mg Tablet Packet</h1>
            <p class="First"><span class="Bold">LIPITOR <span class="Sup">®</span></span><br>(atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>) tablets</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg Tablet Packet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-10.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-24"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 20 mg Tablet Bottle Label</span></p>
            <p>NDC 0071-0156-23</p>
            <p><span class="Bold Italics">Pfizer</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span><br>(atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>)</p>
            <p><span class="Bold">20 mg*</span></p>
            <p><span class="Bold">tablets</span></p>
            <p>90 Tablets<br><span class="Bold">Rx only</span></p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-11.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-25"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 20 mg Tablet <span class="conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span></p>
            <p>(Atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">Calcium</span>)<br>Tablet</p>
            <p><span class="Bold">20 mg</span></p>
            <p>DISTRIBUTED BY:<br>PARKE-DAVIS<br>DIV OF PFIZER INC, NY, NY 10017<br>MADE IN IRELAND</p>
            <p>EXP &amp; LOT AREA</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg Tablet <span class=" conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-12.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-26"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 20 mg <span class="conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack Carton</span></p>
            <p><span class="Bold Italics">Pfizer</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span><br>(atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>)</p>
            <p><span class="Bold">20 mg*</span></p>
            <p><span class="Bold">tablets</span></p>
            <p>For in-institution use only</p>
            <p>100 Tablets</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg <span class=" conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-13.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-27"></a><p></p>
            <h1>PRINCIPAL DISPLAY PANEL - 20 mg Tablet Packet Carton</h1>
            <p class="First">NDC 0071-0156-96<br><span class="Bold">PROFESSIONAL SAMPLE – NOT FOR SALE</span></p>
            <p><span class="Bold Italics">LIPITOR</span><span class="Sub">®</span><br><span class="Italics">atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span><br><span class="Bold">tablets</span></span></p>
            <p><span class="Bold">20 mg*</span><br><span class="Bold Italics">7 TABLETS</span></p>
            <p>PACKAGE NOT CHILD RESISTANT.<br>KEEP OUT OF REACH OF CHILDREN.</p>
            <p><span class="Bold">Rx only</span></p>
            <p><span class="Bold Italics">Patient information enclosed</span></p>
            <p>7 Tablets x 20 mg</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg Tablet Packet Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-14.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-28"></a><p></p>
            <h1>PRINCIPAL DISPLAY PANEL - 20 mg Tablet Packet</h1>
            <p class="First"><span class="Bold">LIPITOR <span class="Sup">®</span></span><br>(atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>) tablets</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg Tablet Packet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-15.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-29"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 40 mg Tablet Bottle Label</span></p>
            <p>NDC 0071-0157-23</p>
            <p><span class="Bold Italics">Pfizer</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span><br>(atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>)</p>
            <p><span class="Bold">40 mg*</span></p>
            <p><span class="Bold">tablets</span></p>
            <p>90 Tablets<br><span class="Bold">Rx only</span></p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 40 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-16.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-30"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 40 mg Tablet <span class="conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span></p>
            <p>(Atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">Calcium</span>)<br>Tablet</p>
            <p><span class="Bold">40 mg</span></p>
            <p>DISTRIBUTED BY:<br>PARKE-DAVIS<br>DIV OF PFIZER INC, NY, NY 10017<br>MADE IN IRELAND</p>
            <p>EXP &amp; LOT AREA</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 40 mg Tablet <span class=" conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-17.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-31"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 40 mg <span class="conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack Carton</span></p>
            <p><span class="Bold Italics">Pfizer</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span><br>(atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>)</p>
            <p><span class="Bold">40 mg*</span></p>
            <p><span class="Bold">tablets</span></p>
            <p>For in-institution use only</p>
            <p>100 Tablets</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 40 mg <span class=" conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-18.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-32"></a><p></p>
            <h1>PRINCIPAL DISPLAY PANEL - 40 mg Tablet Packet Carton</h1>
            <p class="First">NDC 0071-0157-97<br><span class="Bold">PROFESSIONAL SAMPLE – NOT FOR SALE</span></p>
            <p><span class="Bold Italics">LIPITOR</span><span class="Sub">®</span><br><span class="Italics">atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span><br><span class="Bold">tablets</span></span></p>
            <p><span class="Bold">40 mg*</span><br><span class="Bold Italics">7 TABLETS</span></p>
            <p>PACKAGE NOT CHILD RESISTANT.<br>KEEP OUT OF REACH OF CHILDREN.</p>
            <p><span class="Bold">Rx only</span></p>
            <p><span class="Bold Italics">Patient information enclosed</span></p>
            <p>7 Tablets x 40 mg</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 40 mg Tablet Packet Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-19.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-33"></a><p></p>
            <h1>PRINCIPAL DISPLAY PANEL - 40 mg Tablet Packet</h1>
            <p class="First"><span class="Bold">LIPITOR <span class="Sup">®</span></span><br>(atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>) tablets</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 40 mg Tablet Packet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-20.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-34"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 80 mg Tablet Bottle Label</span></p>
            <p>NDC 0071-0158-23</p>
            <p><span class="Bold Italics">Pfizer</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span><br>(atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>)</p>
            <p><span class="Bold">80 mg*</span></p>
            <p><span class="Bold">tablets</span></p>
            <p>90 Tablets<br><span class="Bold">Rx only</span></p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 80 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-21.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-35"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 80 mg Tablet <span class="conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span></p>
            <p>(Atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">Calcium</span>)<br>Tablet</p>
            <p><span class="Bold">80 mg</span></p>
            <p>DISTRIBUTED BY:<br>PARKE-DAVIS<br>DIV OF PFIZER INC, NY, NY 10017<br>MADE IN IRELAND</p>
            <p>EXP &amp; LOT AREA</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 80 mg Tablet <span class=" conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-22.jpg"></div>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="section-36"></a><p></p>
            <p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 80 mg <span class="conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack Carton</span></p>
            <p><span class="Bold Italics">Pfizer</span></p>
            <p><span class="Bold">Lipitor</span><span class="Sup">®</span><br>(atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span>)</p>
            <p><span class="Bold">80 mg*</span></p>
            <p><span class="Bold">tablets</span></p>
            <p>For in-institution use only</p>
            <p>64 Tablets</p>
            <div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 80 mg <span class=" conditions" mdrptid="36211383" mdrpt="blister">Blister</span> Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228&amp;name=lipitor-23.jpg"></div>
        </div>
    </div>
    <div class="DataElementsTables">
        <table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%">
            <tbody>
                <tr>
                    <td class="contentTableTitle">
                        <strong>
                            LIPITOR
                        </strong><br><span class="contentTableReg">atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> tablet, film coated</span>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Product Type</td>
                                <td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
                                <td class="formLabel">Item Code (Source)</td>
                                <td class="formItem">NDC:0071-0155</td>
                            </tr>
                            <tr class="formTableRow">
                                <td width="30%" class="formLabel">Route of Administration</td>
                                <td class="formItem">ORAL</td>
                                <td width="30%" class="formLabel">DEA Schedule</td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
                            <tr>
                                <th class="formTitle" scope="col">Ingredient Name</th>
                                <th class="formTitle" scope="col">Basis of Strength</th>
                                <th class="formTitle" scope="col">Strength</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem">
                                    <strong>ATORVASTATIN <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">CALCIUM</span> TRIHYDRATE</strong> (ATORVASTATIN)
                                </td>
                                <td class="formItem">ATORVASTATIN</td>
                                <td class="formItem">10 mg</td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
                            <tr>
                                <th class="formTitle" scope="col">Ingredient Name</th>
                                <th class="formTitle" scope="col">Strength</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong><span class="conditions" mdrptid="36316341" mdrpt="blood calcium">CALCIUM</span> CARBONATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>CANDELILLA WAX</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>CROSCARMELLOSE <span class="conditions" mdrptid="36316389" mdrpt="blood sodium">SODIUM</span></strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>HYPROMELLOSES</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>TALC</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>POLYSORBATE 80</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Color</td>
                                <td class="formItem">WHITE</td>
                                <td class="formLabel">Score</td>
                                <td class="formItem">no score</td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formLabel">Shape</td>
                                <td class="formItem">OVAL (elliptical) </td>
                                <td class="formLabel">Size</td>
                                <td class="formItem">10mm</td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Flavor</td>
                                <td class="formItem"></td>
                                <td class="formLabel">Imprint Code</td>
                                <td class="formItem">PD;155;10</td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formLabel">Contains</td>
                                <td class="formItem">    </td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
                            <tr>
                                <th scope="col" width="1" class="formTitle">#</th>
                                <th scope="col" class="formTitle">Item Code</th>
                                <th scope="col" class="formTitle">Package Description</th>
                                <th scope="col" class="formTitle">Marketing Start Date</th>
                                <th scope="col" class="formTitle">Marketing End Date</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">1</th>
                                <td class="formItem">NDC:0071-0155-23</td>
                                <td class="formItem">90  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRow">
                                <th scope="row" class="formItem">2</th>
                                <td class="formItem">NDC:0071-0155-34</td>
                                <td class="formItem">5000  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">3</th>
                                <td class="formItem">NDC:0071-0155-40</td>
                                <td class="formItem">100  in 1 CARTON</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">3</th>
                                <td class="formItem"></td>
                                <td class="formItem">1  in 1 <span class="conditions" mdrptid="36211383" mdrpt="blister">BLISTER</span> PACK</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRow">
                                <th scope="row" class="formItem">4</th>
                                <td class="formItem">NDC:0071-0155-10</td>
                                <td class="formItem">1000  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">5</th>
                                <td class="formItem">NDC:0071-0155-97</td>
                                <td class="formItem">1  in 1 CARTON</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">5</th>
                                <td class="formItem"></td>
                                <td class="formItem">7  in 1 PACKET</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr><td></td></tr>
                <tr>
                    <td class="normalizer">
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
                            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
                            <tr>
                                <th scope="col" class="formTitle">Marketing Category</th>
                                <th scope="col" class="formTitle">Application Number or Monograph Citation</th>
                                <th scope="col" class="formTitle">Marketing Start Date</th>
                                <th scope="col" class="formTitle">Marketing End Date</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem">NDA</td>
                                <td class="formItem">NDA020702</td>
                                <td class="formItem">12/17/1996</td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
            </tbody>
        </table>
        <table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%">
            <tbody>
                <tr>
                    <td class="contentTableTitle">
                        <strong>
                            LIPITOR
                        </strong><br><span class="contentTableReg">atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> tablet, film coated</span>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Product Type</td>
                                <td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
                                <td class="formLabel">Item Code (Source)</td>
                                <td class="formItem">NDC:0071-0156</td>
                            </tr>
                            <tr class="formTableRow">
                                <td width="30%" class="formLabel">Route of Administration</td>
                                <td class="formItem">ORAL</td>
                                <td width="30%" class="formLabel">DEA Schedule</td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
                            <tr>
                                <th class="formTitle" scope="col">Ingredient Name</th>
                                <th class="formTitle" scope="col">Basis of Strength</th>
                                <th class="formTitle" scope="col">Strength</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem">
                                    <strong>ATORVASTATIN <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">CALCIUM</span> TRIHYDRATE</strong> (ATORVASTATIN)
                                </td>
                                <td class="formItem">ATORVASTATIN</td>
                                <td class="formItem">20 mg</td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
                            <tr>
                                <th class="formTitle" scope="col">Ingredient Name</th>
                                <th class="formTitle" scope="col">Strength</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong><span class="conditions" mdrptid="36316341" mdrpt="blood calcium">CALCIUM</span> CARBONATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>CANDELILLA WAX</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>CROSCARMELLOSE <span class="conditions" mdrptid="36316389" mdrpt="blood sodium">SODIUM</span></strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>HYPROMELLOSES</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>TALC</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>POLYSORBATE 80</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Color</td>
                                <td class="formItem">WHITE</td>
                                <td class="formLabel">Score</td>
                                <td class="formItem">no score</td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formLabel">Shape</td>
                                <td class="formItem">OVAL (elliptical) </td>
                                <td class="formLabel">Size</td>
                                <td class="formItem">12mm</td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Flavor</td>
                                <td class="formItem"></td>
                                <td class="formLabel">Imprint Code</td>
                                <td class="formItem">PD;156;20</td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formLabel">Contains</td>
                                <td class="formItem">    </td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
                            <tr>
                                <th scope="col" width="1" class="formTitle">#</th>
                                <th scope="col" class="formTitle">Item Code</th>
                                <th scope="col" class="formTitle">Package Description</th>
                                <th scope="col" class="formTitle">Marketing Start Date</th>
                                <th scope="col" class="formTitle">Marketing End Date</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">1</th>
                                <td class="formItem">NDC:0071-0156-23</td>
                                <td class="formItem">90  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRow">
                                <th scope="row" class="formItem">2</th>
                                <td class="formItem">NDC:0071-0156-94</td>
                                <td class="formItem">5000  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">3</th>
                                <td class="formItem">NDC:0071-0156-40</td>
                                <td class="formItem">100  in 1 CARTON</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">3</th>
                                <td class="formItem"></td>
                                <td class="formItem">1  in 1 <span class="conditions" mdrptid="36211383" mdrpt="blister">BLISTER</span> PACK</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRow">
                                <th scope="row" class="formItem">4</th>
                                <td class="formItem">NDC:0071-0156-10</td>
                                <td class="formItem">1000  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">5</th>
                                <td class="formItem">NDC:0071-0156-96</td>
                                <td class="formItem">1  in 1 CARTON</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">5</th>
                                <td class="formItem"></td>
                                <td class="formItem">7  in 1 PACKET</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr><td></td></tr>
                <tr>
                    <td class="normalizer">
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
                            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
                            <tr>
                                <th scope="col" class="formTitle">Marketing Category</th>
                                <th scope="col" class="formTitle">Application Number or Monograph Citation</th>
                                <th scope="col" class="formTitle">Marketing Start Date</th>
                                <th scope="col" class="formTitle">Marketing End Date</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem">NDA</td>
                                <td class="formItem">NDA020702</td>
                                <td class="formItem">12/17/1996</td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
            </tbody>
        </table>
        <table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%">
            <tbody>
                <tr>
                    <td class="contentTableTitle">
                        <strong>
                            LIPITOR
                        </strong><br><span class="contentTableReg">atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> tablet, film coated</span>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Product Type</td>
                                <td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
                                <td class="formLabel">Item Code (Source)</td>
                                <td class="formItem">NDC:0071-0157</td>
                            </tr>
                            <tr class="formTableRow">
                                <td width="30%" class="formLabel">Route of Administration</td>
                                <td class="formItem">ORAL</td>
                                <td width="30%" class="formLabel">DEA Schedule</td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
                            <tr>
                                <th class="formTitle" scope="col">Ingredient Name</th>
                                <th class="formTitle" scope="col">Basis of Strength</th>
                                <th class="formTitle" scope="col">Strength</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem">
                                    <strong>ATORVASTATIN <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">CALCIUM</span> TRIHYDRATE</strong> (ATORVASTATIN)
                                </td>
                                <td class="formItem">ATORVASTATIN</td>
                                <td class="formItem">40 mg</td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
                            <tr>
                                <th class="formTitle" scope="col">Ingredient Name</th>
                                <th class="formTitle" scope="col">Strength</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong><span class="conditions" mdrptid="36316341" mdrpt="blood calcium">CALCIUM</span> CARBONATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>CANDELILLA WAX</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>CROSCARMELLOSE <span class="conditions" mdrptid="36316389" mdrpt="blood sodium">SODIUM</span></strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>HYPROMELLOSES</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>TALC</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>POLYSORBATE 80</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Color</td>
                                <td class="formItem">WHITE</td>
                                <td class="formLabel">Score</td>
                                <td class="formItem">no score</td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formLabel">Shape</td>
                                <td class="formItem">OVAL (elliptical) </td>
                                <td class="formLabel">Size</td>
                                <td class="formItem">15mm</td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Flavor</td>
                                <td class="formItem"></td>
                                <td class="formLabel">Imprint Code</td>
                                <td class="formItem">PD;157;40</td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formLabel">Contains</td>
                                <td class="formItem">    </td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
                            <tr>
                                <th scope="col" width="1" class="formTitle">#</th>
                                <th scope="col" class="formTitle">Item Code</th>
                                <th scope="col" class="formTitle">Package Description</th>
                                <th scope="col" class="formTitle">Marketing Start Date</th>
                                <th scope="col" class="formTitle">Marketing End Date</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">1</th>
                                <td class="formItem">NDC:0071-0157-23</td>
                                <td class="formItem">90  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRow">
                                <th scope="row" class="formItem">2</th>
                                <td class="formItem">NDC:0071-0157-73</td>
                                <td class="formItem">500  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">3</th>
                                <td class="formItem">NDC:0071-0157-88</td>
                                <td class="formItem">2500  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRow">
                                <th scope="row" class="formItem">4</th>
                                <td class="formItem">NDC:0071-0157-40</td>
                                <td class="formItem">100  in 1 CARTON</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRow">
                                <th scope="row" class="formItem">4</th>
                                <td class="formItem"></td>
                                <td class="formItem">1  in 1 <span class="conditions" mdrptid="36211383" mdrpt="blister">BLISTER</span> PACK</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">5</th>
                                <td class="formItem">NDC:0071-0157-97</td>
                                <td class="formItem">1  in 1 CARTON</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">5</th>
                                <td class="formItem"></td>
                                <td class="formItem">7  in 1 PACKET</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr><td></td></tr>
                <tr>
                    <td class="normalizer">
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
                            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
                            <tr>
                                <th scope="col" class="formTitle">Marketing Category</th>
                                <th scope="col" class="formTitle">Application Number or Monograph Citation</th>
                                <th scope="col" class="formTitle">Marketing Start Date</th>
                                <th scope="col" class="formTitle">Marketing End Date</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem">NDA</td>
                                <td class="formItem">NDA020702</td>
                                <td class="formItem">12/17/1996</td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
            </tbody>
        </table>
        <table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%">
            <tbody>
                <tr>
                    <td class="contentTableTitle">
                        <strong>
                            LIPITOR
                        </strong><br><span class="contentTableReg">atorvastatin <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">calcium</span> tablet, film coated</span>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Product Type</td>
                                <td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
                                <td class="formLabel">Item Code (Source)</td>
                                <td class="formItem">NDC:0071-0158</td>
                            </tr>
                            <tr class="formTableRow">
                                <td width="30%" class="formLabel">Route of Administration</td>
                                <td class="formItem">ORAL</td>
                                <td width="30%" class="formLabel">DEA Schedule</td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
                            <tr>
                                <th class="formTitle" scope="col">Ingredient Name</th>
                                <th class="formTitle" scope="col">Basis of Strength</th>
                                <th class="formTitle" scope="col">Strength</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem">
                                    <strong>ATORVASTATIN <span class="conditions" mdrptid="36316341" mdrpt="blood calcium">CALCIUM</span> TRIHYDRATE</strong> (ATORVASTATIN)
                                </td>
                                <td class="formItem">ATORVASTATIN</td>
                                <td class="formItem">80 mg</td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
                            <tr>
                                <th class="formTitle" scope="col">Ingredient Name</th>
                                <th class="formTitle" scope="col">Strength</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong><span class="conditions" mdrptid="36316341" mdrpt="blood calcium">CALCIUM</span> CARBONATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>CANDELILLA WAX</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>CROSCARMELLOSE <span class="conditions" mdrptid="36316389" mdrpt="blood sodium">SODIUM</span></strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>HYPROMELLOSES</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>TALC</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>POLYSORBATE 80</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Color</td>
                                <td class="formItem">WHITE</td>
                                <td class="formLabel">Score</td>
                                <td class="formItem">no score</td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formLabel">Shape</td>
                                <td class="formItem">OVAL (elliptical) </td>
                                <td class="formLabel">Size</td>
                                <td class="formItem">19mm</td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Flavor</td>
                                <td class="formItem"></td>
                                <td class="formLabel">Imprint Code</td>
                                <td class="formItem">PD;158;80</td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formLabel">Contains</td>
                                <td class="formItem">    </td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
                            <tr>
                                <th scope="col" width="1" class="formTitle">#</th>
                                <th scope="col" class="formTitle">Item Code</th>
                                <th scope="col" class="formTitle">Package Description</th>
                                <th scope="col" class="formTitle">Marketing Start Date</th>
                                <th scope="col" class="formTitle">Marketing End Date</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">1</th>
                                <td class="formItem">NDC:0071-0158-23</td>
                                <td class="formItem">90  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRow">
                                <th scope="row" class="formItem">2</th>
                                <td class="formItem">NDC:0071-0158-73</td>
                                <td class="formItem">500  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">3</th>
                                <td class="formItem">NDC:0071-0158-88</td>
                                <td class="formItem">2500  in 1 BOTTLE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRow">
                                <th scope="row" class="formItem">4</th>
                                <td class="formItem">NDC:0071-0158-92</td>
                                <td class="formItem">64  in 1 CARTON</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                            <tr class="formTableRow">
                                <th scope="row" class="formItem">4</th>
                                <td class="formItem"></td>
                                <td class="formItem">1  in 1 <span class="conditions" mdrptid="36211383" mdrpt="blister">BLISTER</span> PACK</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr><td></td></tr>
                <tr>
                    <td class="normalizer">
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
                            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
                            <tr>
                                <th scope="col" class="formTitle">Marketing Category</th>
                                <th scope="col" class="formTitle">Application Number or Monograph Citation</th>
                                <th scope="col" class="formTitle">Marketing Start Date</th>
                                <th scope="col" class="formTitle">Marketing End Date</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem">NDA</td>
                                <td class="formItem">NDA020702</td>
                                <td class="formItem">04/07/2000</td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
            </tbody>
        </table>
        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
            <tr>
                <td colspan="4" class="formHeadingReg">
                    <span class="formHeadingTitle">Labeler - </span>Parke-Davis Div of Pfizer Inc
                    (829076962)
                </td>
            </tr>
        </table>
        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
            <tr>
                <td colspan="4" class="formHeadingReg">
                    <span class="formHeadingTitle">Registrant - </span>Pfizer Inc (113480771)
                </td>
            </tr>
        </table>
        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
            <tr>
                <th scope="col" class="formTitle">Name</th>
                <th scope="col" class="formTitle">Address</th>
                <th scope="col" class="formTitle">ID/FEI</th>
                <th scope="col" class="formTitle">Business Operations</th>
            </tr>
            <tr class="formTableRowAlt">
                <td class="formItem">Pfizer Ireland Pharmaceuticals</td>
                <td class="formItem"></td>
                <td class="formItem">989811526</td>
                <td class="formItem">API MANUFACTURE(0071-0158, 0071-0157, 0071-0156, 0071-0155)</td>
            </tr>
        </table>
        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
            <tr>
                <th scope="col" class="formTitle">Name</th>
                <th scope="col" class="formTitle">Address</th>
                <th scope="col" class="formTitle">ID/FEI</th>
                <th scope="col" class="formTitle">Business Operations</th>
            </tr>
            <tr class="formTableRowAlt">
                <td class="formItem">Pfizer Ireland Pharmaceuticals</td>
                <td class="formItem"></td>
                <td class="formItem">896090987</td>
                <td class="formItem">API MANUFACTURE(0071-0158, 0071-0157, 0071-0156, 0071-0155)</td>
            </tr>
        </table>
        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
            <tr>
                <th scope="col" class="formTitle">Name</th>
                <th scope="col" class="formTitle">Address</th>
                <th scope="col" class="formTitle">ID/FEI</th>
                <th scope="col" class="formTitle">Business Operations</th>
            </tr>
            <tr class="formTableRowAlt">
                <td class="formItem">Pfizer Pharmaceuticals LLC</td>
                <td class="formItem"></td>
                <td class="formItem">829084552</td>
                <td class="formItem">ANALYSIS(0071-0158, 0071-0157, 0071-0156, 0071-0155), MANUFACTURE(0071-0158, 0071-0157, 0071-0156, 0071-0155), PACK(0071-0158, 0071-0157, 0071-0156, 0071-0155)</td>
            </tr>
        </table>
        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
            <tr>
                <th scope="col" class="formTitle">Name</th>
                <th scope="col" class="formTitle">Address</th>
                <th scope="col" class="formTitle">ID/FEI</th>
                <th scope="col" class="formTitle">Business Operations</th>
            </tr>
            <tr class="formTableRowAlt">
                <td class="formItem">Pfizer Asia Pacific PTE LTD</td>
                <td class="formItem"></td>
                <td class="formItem">894677996</td>
                <td class="formItem">API MANUFACTURE(0071-0158, 0071-0157, 0071-0156, 0071-0155)</td>
            </tr>
        </table>
        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
            <tr>
                <th scope="col" class="formTitle">Name</th>
                <th scope="col" class="formTitle">Address</th>
                <th scope="col" class="formTitle">ID/FEI</th>
                <th scope="col" class="formTitle">Business Operations</th>
            </tr>
            <tr class="formTableRowAlt">
                <td class="formItem">Pfizer Manufacturing Deutschland GmbH (Betriebsstätte Freiburg)</td>
                <td class="formItem"></td>
                <td class="formItem">341970073</td>
                <td class="formItem">ANALYSIS(0071-0158, 0071-0157, 0071-0156, 0071-0155), API MANUFACTURE(0071-0158, 0071-0157, 0071-0156, 0071-0155), MANUFACTURE(0071-0158, 0071-0157, 0071-0156, 0071-0155), PACK(0071-0158, 0071-0157, 0071-0156, 0071-0155)</td>
            </tr>
        </table>
        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
            <tr>
                <th scope="col" class="formTitle">Name</th>
                <th scope="col" class="formTitle">Address</th>
                <th scope="col" class="formTitle">ID/FEI</th>
                <th scope="col" class="formTitle">Business Operations</th>
            </tr>
            <tr class="formTableRowAlt">
                <td class="formItem">Pfizer Ireland Pharmaceuticals</td>
                <td class="formItem"></td>
                <td class="formItem">986948909</td>
                <td class="formItem">ANALYSIS(0071-0158, 0071-0157, 0071-0156, 0071-0155), MANUFACTURE(0071-0158, 0071-0157, 0071-0156, 0071-0155)</td>
            </tr>
        </table>
    </div>
    <p>
        <div class="EffectiveDate">
            Revised: 5/2014<div class="DocumentMetadata">
                <div>
                    <a href="javascript:toggleMixin();">Document Id: </a>be9f7e70-f7af-46bc-a336-e352d20b1685
                </div>
                <div>Set id: c6e131fe-e7df-4876-83f7-9156fc4e8228</div>
                <div>Version: 12</div>
                <div>Effective Time: 20140521</div>
            </div>
        </div> <div class="DistributorName">Parke-Davis Div of Pfizer Inc</div>
    </p>
</body>
</html>